1
|
Khaitov M, Shilovskiy I, Valenta R, Weber M, Korneev A, Tulaeva I, Gattinger P, van Hage M, Hofer G, Konradsen JR, Keller W, Akinfenwa O, Poroshina A, Ilina N, Fedenko E, Elisyutina O, Litovkina A, Smolnikov E, Nikonova A, Rybalkin S, Aldobaev V, Smirnov V, Shershakova N, Petukhova O, Kudlay D, Shatilov A, Timofeeva A, Campana R, Udin S, Skvortsova V. Recombinant PreS-fusion protein vaccine for birch pollen and apple allergy. Allergy 2024; 79:1001-1017. [PMID: 37855043 DOI: 10.1111/all.15919] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2023] [Revised: 09/12/2023] [Accepted: 09/25/2023] [Indexed: 10/20/2023]
Abstract
BACKGROUND IgE cross-sensitization to major birch pollen allergen Bet v 1 and pathogenesis-related (PR10) plant food allergens is responsible for the pollen-food allergy syndrome. METHODS We designed a recombinant protein, AB-PreS, consisting of non-allergenic peptides derived from the IgE-binding sites of Bet v 1 and the cross-reactive apple allergen, Mal d 1, fused to the PreS domain of HBV surface protein as immunological carrier. AB-PreS was expressed in E. coli and purified by chromatography. The allergenic and inflammatory activity of AB-PreS was tested using basophils and PBMCs from birch pollen allergic patients. The ability of antibodies induced by immunization of rabbits with AB-PreS and birch pollen extract-based vaccines to inhibit allergic patients IgE binding to Bet v 1 and Mal d 1 was assessed by ELISA. RESULTS IgE-binding experiments and basophil activation test revealed the hypoallergenic nature of AB-PreS. AB-PreS induced lower T-cell activation and inflammatory cytokine production in cultured PBMCs from allergic patients. IgG antibodies induced by five injections with AB-PreS inhibited allergic patients' IgE binding to Bet v 1 and Mal d 1 better than did IgG induced by up to 30 injections of six licensed birch pollen allergen extract-based vaccines. Additionally, immunization with AB-PreS induced HBV-specific antibodies potentially protecting from infection with HBV. CONCLUSION The recombinant AB-PreS-based vaccine is hypoallergenic and superior over currently registered allergen extract-based vaccines regarding the induction of blocking antibodies to Bet v 1 and Mal d 1 in animals.
Collapse
Affiliation(s)
- Musa Khaitov
- NRC Institute of Immunology, FMBA of Russia, Moscow, Russian Federation
- Pirogov Russian National Research Medical University, Moscow, Russian Federation
| | - Igor Shilovskiy
- NRC Institute of Immunology, FMBA of Russia, Moscow, Russian Federation
| | - Rudolf Valenta
- NRC Institute of Immunology, FMBA of Russia, Moscow, Russian Federation
- Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
- Department of Clinical Immunology and Allergology, Laboratory of Immunopathology, Sechenov First Moscow State Medical University, Moscow, Russian Federation
- Karl Landsteiner University for Healthcare Sciences, Krems, Austria
| | - Milena Weber
- Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Artem Korneev
- NRC Institute of Immunology, FMBA of Russia, Moscow, Russian Federation
| | - Inna Tulaeva
- Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
- Department of Clinical Immunology and Allergology, Laboratory of Immunopathology, Sechenov First Moscow State Medical University, Moscow, Russian Federation
| | - Pia Gattinger
- Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Marianne van Hage
- Department of Medicine Solna, Division of Immunology and Allergy, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
| | - Gerhard Hofer
- Department of Materials and Environmental Chemistry, University of Stockholm, Stockholm, Sweden
| | - Jon R Konradsen
- Department of Women's and Children's Health, Astrid Lindgren Children's Hospital, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
| | - Walter Keller
- Institute of Molecular Biosciences, BioTechMed Graz, University of Graz, Graz, Austria
| | - Oluwatoyin Akinfenwa
- Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Alina Poroshina
- NRC Institute of Immunology, FMBA of Russia, Moscow, Russian Federation
| | - Nataliya Ilina
- NRC Institute of Immunology, FMBA of Russia, Moscow, Russian Federation
| | - Elena Fedenko
- NRC Institute of Immunology, FMBA of Russia, Moscow, Russian Federation
| | - Olga Elisyutina
- NRC Institute of Immunology, FMBA of Russia, Moscow, Russian Federation
- Peoples' Friendship University of Russia (RUDN University), Moscow, Russian Federation
| | - Alla Litovkina
- NRC Institute of Immunology, FMBA of Russia, Moscow, Russian Federation
- Peoples' Friendship University of Russia (RUDN University), Moscow, Russian Federation
| | - Evgenii Smolnikov
- NRC Institute of Immunology, FMBA of Russia, Moscow, Russian Federation
- Peoples' Friendship University of Russia (RUDN University), Moscow, Russian Federation
| | | | - Sergei Rybalkin
- Pirogov Russian National Research Medical University, Moscow, Russian Federation
| | - Vladimir Aldobaev
- Pirogov Russian National Research Medical University, Moscow, Russian Federation
| | - Valeriy Smirnov
- NRC Institute of Immunology, FMBA of Russia, Moscow, Russian Federation
- Sechenov First Moscow State Medical University, Moscow, Russian Federation
| | | | - Olga Petukhova
- NRC Institute of Immunology, FMBA of Russia, Moscow, Russian Federation
| | - Dmitriy Kudlay
- NRC Institute of Immunology, FMBA of Russia, Moscow, Russian Federation
- Sechenov First Moscow State Medical University, Moscow, Russian Federation
| | - Artem Shatilov
- NRC Institute of Immunology, FMBA of Russia, Moscow, Russian Federation
| | | | - Raffaela Campana
- Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Sergei Udin
- Federal State Budgetary Institution "Centre for Strategic Planning and Management of Biomedical Health Risks" of the Federal Medical Biological Agency, Moscow, Russian Federation
| | - Veronica Skvortsova
- Federal Medical Biological Agency of Russia (FMBA Russia), Moscow, Russian Federation
| |
Collapse
|
2
|
Brazhnikov G, Smolnikov E, Litovkina A, Jiang T, Shatilov A, Tulaeva I, Tulaev M, Karaulov A, Poroshina A, Zhernov Y, Focke‐Tejkl M, Weber M, Akinfenwa O, Elisyutina O, Andreev S, Shilovskiy I, Shershakova N, Smirnov V, Fedenko E, Lepeshkova TS, Beltyukov EC, Naumova VV, Kundi M, Khaitov M, Wiedermann U, Valenta R, Campana R. Natural human Bet v 1-specific IgG antibodies recognize non-conformational epitopes whereas IgE reacts with conformational epitopes. Allergy 2023; 78:3136-3153. [PMID: 37701941 PMCID: PMC10952721 DOI: 10.1111/all.15865] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2022] [Revised: 07/06/2023] [Accepted: 07/12/2023] [Indexed: 09/14/2023]
Abstract
BACKGROUND The nature of epitopes on Bet v 1 recognized by natural IgG antibodies of birch pollen allergic patients and birch pollen-exposed but non-sensitized subjects has not been studied in detail. OBJECTIVE To investigate IgE and IgG recognition of Bet v 1 and to study the effects of natural Bet v 1-specific IgG antibodies on IgE recognition of Bet v 1 and Bet v 1-induced basophil activation. METHODS Sera from birch pollen allergic patients (BPA, n = 76), allergic patients without birch pollen allergy (NBPA, n = 40) and non-allergic individuals (NA, n = 48) were tested for IgE, IgG as well as IgG1 and IgG4 reactivity to folded recombinant Bet v 1, two unfolded recombinant Bet v 1 fragments comprising the N-terminal (F1) and C-terminal half of Bet v 1 (F2) and unfolded peptides spanning the corresponding sequences of Bet v 1 and the apple allergen Mal d 1 by ELISA or micro-array analysis. The ability of Bet v 1-specific serum antibodies from non-allergic subjects to inhibit allergic patients IgE or IgG binding to rBet v 1 or to unfolded Bet v 1-derivatives was assessed by competition ELISAs. Furthermore, the ability of serum antibodies from allergic and non-allergic subjects to modulate Bet v 1-induced basophil activation was investigated using rat basophilic leukaemia cells expressing the human FcεRI which had been loaded with IgE from BPA patients. RESULTS IgE antibodies from BPA patients react almost exclusively with conformational epitopes whereas IgG, IgG1 and IgG4 antibodies from BPA, NBPA and NA subjects recognize mainly unfolded and sequential epitopes. IgG competition studies show that IgG specific for unfolded/sequential Bet v 1 epitopes is not inhibited by folded Bet v 1 and hence the latter seem to represent cryptic epitopes. IgG reactivity to Bet v 1 peptides did not correlate with IgG reactivity to the corresponding Mal d 1 peptides and therefore does not seem to be a result of primary sensitization to PR10 allergen-containing food. Natural Bet v 1-specific IgG antibodies inhibited IgE binding to Bet v 1 only poorly and could even enhance Bet v 1-specific basophil activation. CONCLUSION IgE and IgG antibodies from BPA patients and birch pollen-exposed non-sensitized subjects recognize different epitopes. These findings explain why natural allergen-specific IgG do not protect against allergic symptoms and suggest that allergen-specific IgE and IgG have different clonal origin.
Collapse
Affiliation(s)
- Georgii Brazhnikov
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and ImmunologyMedical University of ViennaViennaAustria
- Institute for Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and ImmunologyMedical University of ViennaViennaAustria
| | - Evgenii Smolnikov
- National Research Center Institute of Immunology Federal Medical‐Biological Agency of RussiaMoscowRussia
- Department of Immunology, Institute of MedicineRUDN UniversityMoscowRussia
| | - Alla Litovkina
- National Research Center Institute of Immunology Federal Medical‐Biological Agency of RussiaMoscowRussia
- Department of Immunology, Institute of MedicineRUDN UniversityMoscowRussia
| | - Tianchi Jiang
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and ImmunologyMedical University of ViennaViennaAustria
| | - Artem Shatilov
- National Research Center Institute of Immunology Federal Medical‐Biological Agency of RussiaMoscowRussia
| | - Inna Tulaeva
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and ImmunologyMedical University of ViennaViennaAustria
- Laboratory of Immunopathology, Department of Clinical Immunology and AllergologyI.M. Sechenov First Moscow State Medical University (Sechenov University)MoscowRussia
| | - Mikhail Tulaev
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and ImmunologyMedical University of ViennaViennaAustria
| | - Alexander Karaulov
- Laboratory of Immunopathology, Department of Clinical Immunology and AllergologyI.M. Sechenov First Moscow State Medical University (Sechenov University)MoscowRussia
| | - Alina Poroshina
- National Research Center Institute of Immunology Federal Medical‐Biological Agency of RussiaMoscowRussia
| | - Yury Zhernov
- F. Erismann Institute of Public HealthI.M. Sechenov First Moscow State Medical University (Sechenov University)MoscowRussia
| | - Margarete Focke‐Tejkl
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and ImmunologyMedical University of ViennaViennaAustria
- Karl Landsteiner University of Health SciencesKremsAustria
| | - Milena Weber
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and ImmunologyMedical University of ViennaViennaAustria
| | - Oluwatoyin Akinfenwa
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and ImmunologyMedical University of ViennaViennaAustria
| | - Olga Elisyutina
- National Research Center Institute of Immunology Federal Medical‐Biological Agency of RussiaMoscowRussia
- Department of Immunology, Institute of MedicineRUDN UniversityMoscowRussia
| | - Sergey Andreev
- National Research Center Institute of Immunology Federal Medical‐Biological Agency of RussiaMoscowRussia
| | - Igor Shilovskiy
- National Research Center Institute of Immunology Federal Medical‐Biological Agency of RussiaMoscowRussia
| | - Nadezhda Shershakova
- National Research Center Institute of Immunology Federal Medical‐Biological Agency of RussiaMoscowRussia
| | - Valeriy Smirnov
- National Research Center Institute of Immunology Federal Medical‐Biological Agency of RussiaMoscowRussia
| | - Elena Fedenko
- National Research Center Institute of Immunology Federal Medical‐Biological Agency of RussiaMoscowRussia
| | | | - Evgeny Cronidovich Beltyukov
- Department of Faculty Therapy, Endocrinology, Allergology and ImmunologyUral State Medical UniversityYekaterinburgRussia
| | - Veronika Victorovna Naumova
- Department of Faculty Therapy, Endocrinology, Allergology and ImmunologyUral State Medical UniversityYekaterinburgRussia
| | - Michael Kundi
- Institute for Hygiene and Applied Immunology, Center for Public HealthMedical University of ViennaViennaAustria
| | - Musa Khaitov
- National Research Center Institute of Immunology Federal Medical‐Biological Agency of RussiaMoscowRussia
- Pirogov Russian National Research Medical UniversityMoscowRussia
| | - Ursula Wiedermann
- Institute for Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and ImmunologyMedical University of ViennaViennaAustria
| | - Rudolf Valenta
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and ImmunologyMedical University of ViennaViennaAustria
- National Research Center Institute of Immunology Federal Medical‐Biological Agency of RussiaMoscowRussia
- Laboratory of Immunopathology, Department of Clinical Immunology and AllergologyI.M. Sechenov First Moscow State Medical University (Sechenov University)MoscowRussia
- Karl Landsteiner University of Health SciencesKremsAustria
| | - Raffaela Campana
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and ImmunologyMedical University of ViennaViennaAustria
| |
Collapse
|
3
|
Pfisterer K, Wielscher M, Samardzic D, Weinzettl P, Symmank D, Shaw LE, Campana R, Huang HJ, Farlik M, Bangert C, Vrtala S, Valenta R, Weninger W. Non-IgE-reactive allergen peptides deteriorate the skin barrier in house dust mite-sensitized atopic dermatitis patients. Front Cell Dev Biol 2023; 11:1240289. [PMID: 37675143 PMCID: PMC10478000 DOI: 10.3389/fcell.2023.1240289] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2023] [Accepted: 08/04/2023] [Indexed: 09/08/2023] Open
Abstract
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by type 2 cytokine-driven skin inflammation and epithelial barrier dysfunction. The latter is believed to allow the increased penetration of chemicals, toxins, and allergens into the skin. House dust mite allergens, particularly Der p 2, are important triggers in sensitized individuals with AD; the precise actions of these allergens in epithelial biology remain, however, incompletely understood. In this study, we compared the effects of the protein allergen Der p 2 and a mix of non-IgE-reactive Der p 2 peptides on skin cells using patch tests in AD patients and healthy participants. We then analyzed mRNA expression profiles of keratinocytes by single-cell RNA-sequencing. We report that existing barrier deficiencies in the non-lesional skin of AD patients allow deep penetration of Der p 2 and its peptides, leading to local microinflammation. Der p 2 protein specifically upregulated genes involved in the innate immune system, stress, and danger signals in suprabasal KC. Der p 2 peptides further downregulated skin barrier genes, in particular the expression of genes involved in cell-matrix and cell-cell adhesion. Peptides also induced genes involved in hyperproliferation and caused disturbances in keratinocyte differentiation. Furthermore, inflammasome-relevant genes and IL18 were overexpressed, while KRT1 was downregulated. Our data suggest that Der p 2 peptides contribute to AD initiation and exacerbation by augmenting hallmark features of AD, such as skin inflammation, barrier disruption, and hyperplasia of keratinocytes.
Collapse
Affiliation(s)
- Karin Pfisterer
- Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - Matthias Wielscher
- Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - David Samardzic
- Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - Pauline Weinzettl
- Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - Dorte Symmank
- Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - Lisa E. Shaw
- Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - Raffaela Campana
- Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology, and Immunology, Medical University of Vienna, Vienna, Austria
| | - Huey-Jy Huang
- Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology, and Immunology, Medical University of Vienna, Vienna, Austria
- Karl Landsteiner University of Health Sciences, Krems, Austria
| | - Matthias Farlik
- Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - Christine Bangert
- Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - Susanne Vrtala
- Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology, and Immunology, Medical University of Vienna, Vienna, Austria
| | - Rudolf Valenta
- Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology, and Immunology, Medical University of Vienna, Vienna, Austria
| | - Wolfgang Weninger
- Department of Dermatology, Medical University of Vienna, Vienna, Austria
| |
Collapse
|
4
|
Litovkina A, Byazrova M, Smolnikov E, Nikonova A, Elisyutina O, Fedenko E, Ilina N, Akinfenwa O, Campana R, Kudlay D, Valenta R, Khaitov M. Allergic sensitization to Mal d 1 without detectable specific serum IgE. Pediatr Allergy Immunol 2022; 33:e13891. [PMID: 36564883 PMCID: PMC10107674 DOI: 10.1111/pai.13891] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/14/2022] [Revised: 10/02/2022] [Accepted: 11/09/2022] [Indexed: 12/12/2022]
Affiliation(s)
- Alla Litovkina
- National Research Center, Institute of Immunology FMBA of Russia, Moscow, Russian Federation.,Peoples' Friendship University of Russia (RUDN University), Moscow, Russian Federation
| | - Maria Byazrova
- National Research Center, Institute of Immunology FMBA of Russia, Moscow, Russian Federation.,Peoples' Friendship University of Russia (RUDN University), Moscow, Russian Federation.,Lomonosov Moscow State University, Moscow, Russian Federation
| | - Evgenii Smolnikov
- National Research Center, Institute of Immunology FMBA of Russia, Moscow, Russian Federation.,Peoples' Friendship University of Russia (RUDN University), Moscow, Russian Federation
| | - Alexandra Nikonova
- National Research Center, Institute of Immunology FMBA of Russia, Moscow, Russian Federation.,Peoples' Friendship University of Russia (RUDN University), Moscow, Russian Federation
| | - Olga Elisyutina
- National Research Center, Institute of Immunology FMBA of Russia, Moscow, Russian Federation.,Peoples' Friendship University of Russia (RUDN University), Moscow, Russian Federation
| | - Elena Fedenko
- National Research Center, Institute of Immunology FMBA of Russia, Moscow, Russian Federation
| | - Nataliya Ilina
- National Research Center, Institute of Immunology FMBA of Russia, Moscow, Russian Federation
| | - Oluwatoyin Akinfenwa
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Raffaela Campana
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Dmitry Kudlay
- National Research Center, Institute of Immunology FMBA of Russia, Moscow, Russian Federation.,Department of Clinical Immunology and Allergy, Sechenov First Moscow State Medical University, Moscow, Russian Federation
| | - Rudolf Valenta
- National Research Center, Institute of Immunology FMBA of Russia, Moscow, Russian Federation.,Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.,Department of Clinical Immunology and Allergy, Sechenov First Moscow State Medical University, Moscow, Russian Federation.,Karl Landsteiner University of Health Sciences, Krems, Austria
| | - Musa Khaitov
- National Research Center, Institute of Immunology FMBA of Russia, Moscow, Russian Federation.,Pirogov Russian National Research Medical University, Moscow, Russian Federation
| |
Collapse
|
5
|
Sabatini L, Sisti M, Campana R. Isolation and identification of Legionella spp. from non-hospital facilities: a preliminary one-year surveillance study in the urban area of Pesaro-Urbino (Central Italy). Ann Ig 2022; 34:177-183. [PMID: 35088824 DOI: 10.7416/ai.2022.2477] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
BACKGROUND Legionella is considered one of the most important causes of potentially preventable morbid-ity and mortality. These microorganisms are ubiquitous, but incomplete information is available on the geographic distribution of Legionella species in our region. STUDY DESIGN For the mentioned reasons, in this work the distribution of Legionella spp. in non-hospital facilities of the urban area of Pesaro-Urbino (Central Italy), including public fountains, residential build-ings, public and private offices and retirement homes, was investigated. METHODS A total of 298 water samples were collected from the different facilities and subjected to standard Legionella isolation and identification protocols. RESULTS As reported, 17.8% of the collected water samples resulted positive for Legionella spp. (28.6% from retirement homes, 21.3% from residential buildings, 15.3% from private and public offices). The highest per-centage of positive samples (14.4%) was found in hot water from retirements homes (58.8%) and residential buildings (31.8%); the most frequent isolated serogroups were L. pneumophila 2-14 (71.7%). CONCLUSIONS This work is the first describing the distribution of Legionella spp. in non-hospital facilities in the province of Pesaro-Urbino, and highlights a condition of potential risk for susceptible categories. From our data, we can point that a regular and constant control to prevent microbiological risk from legionellosis, particularly in facilities housing the elderly, is recommended.
Collapse
Affiliation(s)
- L Sabatini
- Department of Biomolecular Sciences, Division of Pharmacology and Hygiene, "Carlo Bo" University, Urbino, Italy
| | - M Sisti
- Department of Biomolecular Sciences, Division of Pharmacology and Hygiene, "Carlo Bo" University, Urbino, Italy
| | - R Campana
- Department of Biomolecular Sciences, Division of Pharmacology and Hygiene, "Carlo Bo" University, Urbino, Italy
| |
Collapse
|
6
|
Akinfenwa O, Huang HJ, Linhart B, Focke-Tejkl M, Vrtala S, Poroshina A, Nikonova A, Khaitov M, Campion NJ, Eckl-Dorna J, Niederberger-Leppin V, Kratzer B, Tauber PA, Pickl WF, Kundi M, Campana R, Valenta R. Preventive Administration of Non-Allergenic Bet v 1 Peptides Reduces Allergic Sensitization to Major Birch Pollen Allergen, Bet v 1. Front Immunol 2021; 12:744544. [PMID: 34795666 PMCID: PMC8594376 DOI: 10.3389/fimmu.2021.744544] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2021] [Accepted: 09/20/2021] [Indexed: 11/15/2022] Open
Abstract
IgE-mediated allergy to birch pollen affects more than 100 million patients world-wide. Bet v 1, a 17 kDa protein is the major allergen in birch pollen responsible for allergic rhinoconjunctivitis and asthma in birch pollen allergic patients. Allergen-specific immunotherapy (AIT) based on therapeutic administration of Bet v 1-containing vaccines is an effective treatment for birch pollen allergy but no allergen-specific forms of prevention are available. We developed a mouse model for IgE sensitization to Bet v 1 based on subcutaneous injection of aluminum-hydroxide adsorbed recombinant Bet v 1 and performed a detailed characterization of the specificities of the IgE, IgG and CD4+ T cell responses in sensitized mice using seven synthetic peptides of 31-42 amino acids length which comprised the Bet v 1 sequence and the epitopes recognized by human CD4+ T cells. We then demonstrate that preventive systemic administration of a mix of synthetic non-allergenic Bet v 1 peptides to 3-4 week old mice significantly reduced allergic immune responses, including IgE, IgG, IgE-mediated basophil activation, CD4+ T cell and IL-4 responses to the complete Bet v 1 allergen but not to the unrelated major grass pollen allergen Phl p 5, without inducing Bet v 1-specific allergic sensitization or adaptive immunity. Our results thus demonstrate that early preventive administration of non-allergenic synthetic T cell epitope-containing allergen peptides could be a safe strategy for the prevention of allergen-specific IgE sensitization.
Collapse
Affiliation(s)
- Oluwatoyin Akinfenwa
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Huey-Jy Huang
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Birgit Linhart
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Margarete Focke-Tejkl
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.,Karl Landsteiner University of Health Sciences, Krems, Austria
| | - Susanne Vrtala
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Alina Poroshina
- National Research Center (NRC) - Institute of Immunology Federal Medical-Biological Agency (FMBA) of Russia, Moscow, Russia
| | - Alexandra Nikonova
- National Research Center (NRC) - Institute of Immunology Federal Medical-Biological Agency (FMBA) of Russia, Moscow, Russia
| | - Musa Khaitov
- National Research Center (NRC) - Institute of Immunology Federal Medical-Biological Agency (FMBA) of Russia, Moscow, Russia.,Immunology Department, Pirogov Russian National Research Medical University, Moscow, Russia
| | - Nicholas J Campion
- Department of Otorhinolaryngology, Medical University of Vienna, Vienna, Austria
| | - Julia Eckl-Dorna
- Department of Otorhinolaryngology, Medical University of Vienna, Vienna, Austria
| | | | - Bernhard Kratzer
- Institute of Immunology, Center for Pathophysiology, Infectiology & Immunology, Medical University of Vienna, Vienna, Austria
| | - Peter Anton Tauber
- Institute of Immunology, Center for Pathophysiology, Infectiology & Immunology, Medical University of Vienna, Vienna, Austria
| | - Winfried F Pickl
- Karl Landsteiner University of Health Sciences, Krems, Austria.,Institute of Immunology, Center for Pathophysiology, Infectiology & Immunology, Medical University of Vienna, Vienna, Austria
| | - Michael Kundi
- Institute for Hygiene and Applied Immunology, Centre for Public Health, Medical University of Vienna, Vienna, Austria
| | - Raffaela Campana
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Rudolf Valenta
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.,Karl Landsteiner University of Health Sciences, Krems, Austria.,National Research Center (NRC) - Institute of Immunology Federal Medical-Biological Agency (FMBA) of Russia, Moscow, Russia.,Laboratory for Immunopathology, Department of Clinical Immunology and Allergy, Sechenov First Moscow State Medical University, Moscow, Russia
| |
Collapse
|
7
|
Huang HJ, Campana R, Akinfenwa O, Curin M, Sarzsinszky E, Karsonova A, Riabova K, Karaulov A, Niespodziana K, Elisyutina O, Fedenko E, Litovkina A, Smolnikov E, Khaitov M, Vrtala S, Schlederer T, Valenta R. Microarray-Based Allergy Diagnosis: Quo Vadis? Front Immunol 2021; 11:594978. [PMID: 33679689 PMCID: PMC7928321 DOI: 10.3389/fimmu.2020.594978] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2020] [Accepted: 12/08/2020] [Indexed: 12/24/2022] Open
Abstract
More than 30% of the world population suffers from allergy. Allergic individuals are characterized by the production of immunoglobulin E (IgE) antibodies against innocuous environmental allergens. Upon allergen recognition IgE mediates allergen-specific immediate and late-phase allergic inflammation in different organs. The identification of the disease-causing allergens by demonstrating the presence of allergen-specific IgE is the key to precision medicine in allergy because it allows tailoring different forms of prevention and treatment according to the sensitization profiles of individual allergic patients. More than 30 years ago molecular cloning started to accelerate the identification of the disease-causing allergen molecules and enabled their production as recombinant molecules. Based on recombinant allergen molecules, molecular allergy diagnosis was introduced into clinical practice and allowed dissecting the molecular sensitization profiles of allergic patients. In 2002 it was demonstrated that microarray technology allows assembling large numbers of allergen molecules on chips for the rapid serological testing of IgE sensitizations with small volumes of serum. Since then microarrayed allergens have revolutionized research and diagnosis in allergy, but several unmet needs remain. Here we show that detection of IgE- and IgG-reactivity to a panel of respiratory allergens microarrayed onto silicon elements is more sensitive than glass-based chips. We discuss the advantages of silicon-based allergen microarrays and how this technology will allow addressing hitherto unmet needs in microarray-based allergy diagnosis. Importantly, it described how the assembly of silicon microarray elements may create different microarray formats for suiting different diagnostic applications such as quick testing of single patients, medium scale testing and fully automated large scale testing.
Collapse
Affiliation(s)
- Huey-Jy Huang
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Raffaela Campana
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Oluwatoyin Akinfenwa
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Mirela Curin
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Eszter Sarzsinszky
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Antonina Karsonova
- Laboratory of Immunopathology, Department of Clinical Immunology and Allergology, Sechenov First Moscow State Medical University, Moscow, Russia
| | - Ksenja Riabova
- Laboratory of Immunopathology, Department of Clinical Immunology and Allergology, Sechenov First Moscow State Medical University, Moscow, Russia
| | - Alexander Karaulov
- Laboratory of Immunopathology, Department of Clinical Immunology and Allergology, Sechenov First Moscow State Medical University, Moscow, Russia
| | - Katarzyna Niespodziana
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Olga Elisyutina
- Department of Allergology and Clinical Immunology, NRC Institute of Immunology FMBA of Russia, Moscow, Russia
| | - Elena Fedenko
- Department of Allergology and Clinical Immunology, NRC Institute of Immunology FMBA of Russia, Moscow, Russia
| | - Alla Litovkina
- Department of Allergology and Clinical Immunology, NRC Institute of Immunology FMBA of Russia, Moscow, Russia
| | - Evgenii Smolnikov
- Department of Allergology and Clinical Immunology, NRC Institute of Immunology FMBA of Russia, Moscow, Russia
| | - Musa Khaitov
- Department of Allergology and Clinical Immunology, NRC Institute of Immunology FMBA of Russia, Moscow, Russia
| | - Susanne Vrtala
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Thomas Schlederer
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Rudolf Valenta
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.,Laboratory of Immunopathology, Department of Clinical Immunology and Allergology, Sechenov First Moscow State Medical University, Moscow, Russia.,Department of Allergology and Clinical Immunology, NRC Institute of Immunology FMBA of Russia, Moscow, Russia.,Karl Landsteiner University of Health Sciences, Krems, Austria
| |
Collapse
|
8
|
Abstract
PURPOSE OF REVIEW Allergen-specific immunotherapy (AIT) is a highly economic, effective and disease-modifying form of allergy treatment but requires accurate prescription and monitoring. New molecular approaches are currently under development to improve AIT by reducing treatment-related side effects, cumbersome protocols and patients' compliance. We review the current advances regarding refined diagnosis for prescription and monitoring of AIT and the development of novel molecular vaccines for AIT. Finally, we discuss prophylactic application of AIT. RECENT FINDINGS There is evidence that molecular allergy diagnosis not only assists in the prescription and monitoring of AIT but also allows a refined selection of patients to increase the likelihood of treatment success. New data regarding the effects of AIT treatment with traditional allergen extracts by alternative routes have become available. Experimental approaches for AIT, such as virus-like particles and cell-based treatments have been described. New results from clinical trials performed with recombinant hypoallergens and passive immunization with allergen-specific antibodies highlight the importance of allergen-specific IgG antibodies for the effect of AIT and indicate opportunities for preventive allergen-specific vaccination. SUMMARY Molecular allergy diagnosis is useful for the prescription and monitoring of AIT and may improve the success of AIT. Results with molecular allergy vaccines and by passive immunization with allergen-specific IgG antibodies indicate the importance of allergen-specific IgG capable of blocking allergen recognition by IgE and IgE-mediated allergic inflammation as important mechanism for the success of AIT. New molecular vaccines may pave the road towards prophylactic allergen-specific vaccination.
Collapse
Affiliation(s)
- Oluwatoyin Akinfenwa
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Azahara Rodríguez-Domínguez
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Susanne Vrtala
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Rudolf Valenta
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
- NRC Institute of Immunology FMBA of Russia
- Laboratory for Immunopathology, Department of Clinical Immunology and Allergy, Sechenov First Moscow State Medical University, Moscow, Russia
- Karl Landsteiner University of Health Sciences, Krems, Austria
| | - Raffaela Campana
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| |
Collapse
|
9
|
Karsonova A, Riabova K, Villazala‐Merino S, Campana R, Niederberger V, Eckl‐Dorna J, Fröschl R, Perkmann T, Zhernov YV, Elisyutina OG, Fedenko ES, Khaitov MR, Fomina D, Beltiukov E, Hage M, Grönlund H, Valenta R, Karaulov A, Curin M. Highly sensitive ELISA-based assay for quantification of allergen-specific IgE antibody levels. Allergy 2020; 75:2668-2670. [PMID: 32302409 PMCID: PMC7687237 DOI: 10.1111/all.14325] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2020] [Revised: 04/08/2020] [Accepted: 04/11/2020] [Indexed: 01/07/2023]
Affiliation(s)
- Antonina Karsonova
- Laboratory of Immunopathology Department of Clinical Immunology and Allergy Sechenov First Moscow State Medical University Moscow Russian Federation
| | - Ksenja Riabova
- Laboratory of Immunopathology Department of Clinical Immunology and Allergy Sechenov First Moscow State Medical University Moscow Russian Federation
| | | | - Raffaela Campana
- Division of Immunopathology Department of Pathophysiology and Allergy Research Center for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria
| | - Verena Niederberger
- Department of Otorhinolaryngology Medical University of Vienna Vienna Austria
| | - Julia Eckl‐Dorna
- Department of Otorhinolaryngology Medical University of Vienna Vienna Austria
| | - Renate Fröschl
- Department of Laboratory Medicine Medical University of Vienna Vienna Austria
| | - Thomas Perkmann
- Department of Laboratory Medicine Medical University of Vienna Vienna Austria
| | - Yury V. Zhernov
- National Research Center ‐ Institute of Immunology FMBA of Russia Moscow Russian Federation
| | - Olga G. Elisyutina
- National Research Center ‐ Institute of Immunology FMBA of Russia Moscow Russian Federation
| | - Elena S. Fedenko
- National Research Center ‐ Institute of Immunology FMBA of Russia Moscow Russian Federation
| | - Musa R. Khaitov
- National Research Center ‐ Institute of Immunology FMBA of Russia Moscow Russian Federation
| | - Daria Fomina
- Laboratory of Immunopathology Department of Clinical Immunology and Allergy Sechenov First Moscow State Medical University Moscow Russian Federation
- City Hospital #52 Moscow Russian Federation
| | | | - Marianne Hage
- Division of Immunology and Allergy Department of Medicine Solna Karolinska Institutet and Karolinska University Hospital Stockholm Sweden
| | - Hans Grönlund
- Department of Clinical Neuroscience Therapeutic Immune Design Unit Karolinska Institutet Stockholm Sweden
| | - Rudolf Valenta
- Division of Immunopathology Department of Pathophysiology and Allergy Research Center for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria
- Karl Landsteiner University for Healthcare Sciences Krems Austria
| | - Alexander Karaulov
- Laboratory of Immunopathology Department of Clinical Immunology and Allergy Sechenov First Moscow State Medical University Moscow Russian Federation
| | - Mirela Curin
- Division of Immunopathology Department of Pathophysiology and Allergy Research Center for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria
| |
Collapse
|
10
|
Tulaeva I, Kratzer B, Campana R, Curin M, van Hage M, Karsonova A, Riabova K, Karaulov A, Khaitov M, Pickl WF, Valenta R. Preventive Allergen-Specific Vaccination Against Allergy: Mission Possible? Front Immunol 2020; 11:1368. [PMID: 32733455 PMCID: PMC7358538 DOI: 10.3389/fimmu.2020.01368] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2020] [Accepted: 05/28/2020] [Indexed: 12/17/2022] Open
Abstract
Vaccines for infectious diseases have improved the life of the human species in a tremendous manner. The principle of vaccination is to establish de novo adaptive immune response consisting of antibody and T cell responses against pathogens which should defend the vaccinated person against future challenge with the culprit pathogen. The situation is completely different for immunoglobulin E (IgE)-associated allergy, an immunologically-mediated hypersensitivity which is already characterized by increased IgE antibody levels and T cell responses against per se innocuous antigens (i.e., allergens). Thus, allergic patients suffer from a deviated hyper-immunity against allergens leading to inflammation upon allergen contact. Paradoxically, vaccination with allergens, termed allergen-specific immunotherapy (AIT), induces a counter immune response based on the production of high levels of allergen-specific IgG antibodies and alterations of the adaptive cellular response, which reduce allergen-induced symptoms of allergic inflammation. AIT was even shown to prevent the progression of mild to severe forms of allergy. Consequently, AIT can be considered as a form of therapeutic vaccination. In this article we describe a strategy and possible road map for the use of an AIT approach for prophylactic vaccination against allergy which is based on new molecular allergy vaccines. This road map includes the use of AIT for secondary preventive vaccination to stop the progression of clinically silent allergic sensitization toward symptomatic allergy and ultimately the prevention of allergic sensitization by maternal vaccination and/or early primary preventive vaccination of children. Prophylactic allergy vaccination with molecular allergy vaccines may allow halting the allergy epidemics affecting almost 30% of the population as it has been achieved for vaccination against infectious diseases.
Collapse
Affiliation(s)
- Inna Tulaeva
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.,Laboratory of Immunopathology, Department of Clinical Immunology and Allergology, Sechenov First Moscow State Medical University, Moscow, Russia
| | - Bernhard Kratzer
- Center for Pathophysiology, Infectiology and Immunology, Institute of Immunology, Medical University of Vienna, Vienna, Austria
| | - Raffaela Campana
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Mirela Curin
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Marianne van Hage
- Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - Antonina Karsonova
- Laboratory of Immunopathology, Department of Clinical Immunology and Allergology, Sechenov First Moscow State Medical University, Moscow, Russia
| | - Ksenja Riabova
- Laboratory of Immunopathology, Department of Clinical Immunology and Allergology, Sechenov First Moscow State Medical University, Moscow, Russia
| | - Alexander Karaulov
- Laboratory of Immunopathology, Department of Clinical Immunology and Allergology, Sechenov First Moscow State Medical University, Moscow, Russia
| | - Musa Khaitov
- NRC Institute of Immunology FMBA of Russia, Moscow, Russia
| | - Winfried F Pickl
- Center for Pathophysiology, Infectiology and Immunology, Institute of Immunology, Medical University of Vienna, Vienna, Austria
| | - Rudolf Valenta
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.,Laboratory of Immunopathology, Department of Clinical Immunology and Allergology, Sechenov First Moscow State Medical University, Moscow, Russia.,NRC Institute of Immunology FMBA of Russia, Moscow, Russia.,Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria
| |
Collapse
|
11
|
Rauber MM, Möbs C, Campana R, Henning R, Schulze‐Dasbeck M, Greene B, Focke‐Tejkl M, Weber M, Valenta R, Pfützner W. Allergen immunotherapy with the hypoallergenic B-cell epitope-based vaccine BM32 modifies IL-10- and IL-5-secreting T cells. Allergy 2020; 75:450-453. [PMID: 31330050 DOI: 10.1111/all.13996] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- Michèle Myriam Rauber
- Clinical & Experimental Allergology, Department of Dermatology and Allergology Philipps‐Universität Marburg Marburg Germany
- Experimental Dermatology and Allergy Research Justus‐Liebig‐University Giessen Giessen Germany
| | - Christian Möbs
- Clinical & Experimental Allergology, Department of Dermatology and Allergology Philipps‐Universität Marburg Marburg Germany
| | - Raffaela Campana
- Department of Pathophysiology and Allergy Research Medical University Vienna Vienna Austria
| | | | - Manuel Schulze‐Dasbeck
- Clinical & Experimental Allergology, Department of Dermatology and Allergology Philipps‐Universität Marburg Marburg Germany
| | - Brandon Greene
- Institute of Medical Biometry and Epidemiology Philipps‐Universität Marburg Marburg Germany
| | - Margarete Focke‐Tejkl
- Department of Pathophysiology and Allergy Research Medical University Vienna Vienna Austria
| | - Milena Weber
- Department of Pathophysiology and Allergy Research Medical University Vienna Vienna Austria
| | - Rudolf Valenta
- Department of Pathophysiology and Allergy Research Medical University Vienna Vienna Austria
- NRC Institute of Immunology FMBA of Russia Moscow Russia
- Laboratory of Immunopathology, Department of Clinical Immunology and Allergy Sechenov First Moscow State Medical University Moscow Russia
| | - Wolfgang Pfützner
- Clinical & Experimental Allergology, Department of Dermatology and Allergology Philipps‐Universität Marburg Marburg Germany
| |
Collapse
|
12
|
Elisyutina O, Fedenko E, Campana R, Litovkina A, Ilina N, Kudlay D, Egorenkov E, Smirnov V, Valenta R, Lupinek C, Khaitov M. Bet v 1-specific IgE levels and PR-10 reactivity discriminate silent sensitization from phenotypes of birch allergy. Allergy 2019; 74:2525-2528. [PMID: 31145475 DOI: 10.1111/all.13931] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Affiliation(s)
| | - Elena Fedenko
- NRC Institute of Immunology FMBA of Russia Moscow Russia
| | - Raffaela Campana
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Centre for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria
| | - Alla Litovkina
- NRC Institute of Immunology FMBA of Russia Moscow Russia
| | - Nataliya Ilina
- NRC Institute of Immunology FMBA of Russia Moscow Russia
| | - Dmitry Kudlay
- NRC Institute of Immunology FMBA of Russia Moscow Russia
| | | | - Valeriy Smirnov
- NRC Institute of Immunology FMBA of Russia Moscow Russia
- Sechenov First State Medical University Moscow Russian Federation
| | - Rudolf Valenta
- NRC Institute of Immunology FMBA of Russia Moscow Russia
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Centre for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria
- Sechenov First State Medical University Moscow Russian Federation
| | - Christian Lupinek
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Centre for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria
| | - Musa Khaitov
- NRC Institute of Immunology FMBA of Russia Moscow Russia
| |
Collapse
|
13
|
Huang H, Curin M, Banerjee S, Chen K, Garmatiuk T, Resch‐Marat Y, Carvalho‐Queiroz C, Blatt K, Gafvelin G, Grönlund H, Valent P, Campana R, Focke‐Tejkl M, Valenta R, Vrtala S. A hypoallergenic peptide mix containing T cell epitopes of the clinically relevant house dust mite allergens. Allergy 2019; 74:2461-2478. [PMID: 31228873 PMCID: PMC7078969 DOI: 10.1111/all.13956] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2018] [Revised: 04/29/2019] [Accepted: 05/01/2019] [Indexed: 12/31/2022]
Abstract
Background In the house dust mite (HDM) Dermatophagoides pteronyssinus, Der p 1, 2, 5, 7, 21, and 23 have been identified as the most important allergens. The aim of this study was to define hypoallergenic peptides derived from the sequences of the six allergens and to use the peptides and the complete allergens to study antibody, T cell, and cytokine responses in sensitized and nonsensitized subjects. Methods IgE reactivity of HDM‐allergic and non‐HDM‐sensitized individuals to 15 HDM allergens was established using ImmunoCAP ISAC technology. Thirty‐three peptides covering the sequences of the six HDM allergens were synthesized. Allergens and peptides were tested for IgE and IgG reactivity by ELISA and ImmunoCAP, respectively. Allergenic activity was determined by basophil activation. CD4+ T cell and cytokine responses were determined in PBMC cultures by CFSE dilution and Luminex technology, respectively. Results House dust mite allergics showed IgE reactivity only to complete allergens, whereas 31 of the 33 peptides lacked relevant IgE reactivity and allergenic activity. IgG antibodies of HDM‐allergic and nonsensitized subjects were directed against peptide epitopes and higher allergen‐specific IgG levels were found in HDM allergics. PBMC from HDM‐allergics produced higher levels of IL‐5 whereas non‐HDM‐sensitized individuals mounted higher levels of IFN‐gamma, IL‐17, pro‐inflammatory cytokines, and IL‐10. Conclusion IgG antibodies in HDM‐allergic patients recognize peptide epitopes which are different from the epitopes recognized by IgE. This may explain why naturally occurring allergen‐specific IgG antibodies do not protect against IgE‐mediated allergic inflammation. A mix of hypoallergenic peptides containing T cell epitopes of the most important HDM allergens was identified.
Collapse
Affiliation(s)
- Huey‐Jy Huang
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria
| | - Mirela Curin
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria
| | - Srinita Banerjee
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria
| | - Kuan‐Wei Chen
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria
| | - Tetiana Garmatiuk
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria
| | - Yvonne Resch‐Marat
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria
| | - Claudia Carvalho‐Queiroz
- Department of Clinical Neuroscience, Therapeutic Immune Design Unit Karolinska Institutet Stockholm Sweden
| | - Katharina Blatt
- Division of Hematology&Hemostaseology, Department of Internal Medicine I Medical University of Vienna Vienna Austria
| | - Guro Gafvelin
- Department of Clinical Neuroscience, Therapeutic Immune Design Unit Karolinska Institutet Stockholm Sweden
| | - Hans Grönlund
- Department of Clinical Neuroscience, Therapeutic Immune Design Unit Karolinska Institutet Stockholm Sweden
| | - Peter Valent
- Division of Hematology&Hemostaseology, Department of Internal Medicine I Medical University of Vienna Vienna Austria
| | - Raffaela Campana
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria
| | - Margarete Focke‐Tejkl
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria
| | - Rudolf Valenta
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria
- NRC Institute of Immunology FMBA of Russia Moscow Russia
- Department of Clinical Immunology and Allergy, Laboratory for Immunopathology Sechenov First Moscow State Medical University Moscow Russia
| | - Susanne Vrtala
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria
| |
Collapse
|
14
|
Campana R, Marth K, Zieglmayer P, Weber M, Lupinek C, Zhernov Y, Elisyutina O, Khaitov M, Rigler E, Westritschnig K, Berger U, Wolkersdorfer M, Horak F, Horak F, Valenta R. Vaccination of nonallergic individuals with recombinant hypoallergenic fragments of birch pollen allergen Bet v 1: Safety, effects, and mechanisms. J Allergy Clin Immunol 2018; 143:1258-1261. [PMID: 30471304 PMCID: PMC6411133 DOI: 10.1016/j.jaci.2018.11.011] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2017] [Revised: 10/31/2018] [Accepted: 11/09/2018] [Indexed: 11/06/2022]
Affiliation(s)
- Raffaela Campana
- Department of Pathophysiology and Allergy Research, Medical University of Vienna, Waehringer Guertel, Vienna, Austria
| | - Katharina Marth
- Department of Pathophysiology and Allergy Research, Medical University of Vienna, Waehringer Guertel, Vienna, Austria
| | | | - Milena Weber
- Department of Pathophysiology and Allergy Research, Medical University of Vienna, Waehringer Guertel, Vienna, Austria
| | - Christian Lupinek
- Department of Pathophysiology and Allergy Research, Medical University of Vienna, Waehringer Guertel, Vienna, Austria
| | - Yury Zhernov
- NRC Institute of Immunology FMBA of Russia, Moscow, Russia
| | | | - Musa Khaitov
- NRC Institute of Immunology FMBA of Russia, Moscow, Russia
| | - Eva Rigler
- Department of Pathophysiology and Allergy Research, Medical University of Vienna, Waehringer Guertel, Vienna, Austria
| | - Kerstin Westritschnig
- Department of Pathophysiology and Allergy Research, Medical University of Vienna, Waehringer Guertel, Vienna, Austria
| | - Uwe Berger
- Department of Oto-Rhino-Laryngology, Medical University of Vienna, Vienna, Austria
| | - Martin Wolkersdorfer
- Department of Production, Landesapotheke Salzburg, Muellner Hauptstraße, Salzburg, Austria
| | - Fritz Horak
- Allergy Center Vienna West, Huetteldorfer Straße, Vienna, Austria
| | - Friedrich Horak
- Vienna Challenge Chamber, Huetteldorfer Straße, Vienna, Austria; Allergy Center Vienna West, Huetteldorfer Straße, Vienna, Austria
| | - Rudolf Valenta
- Department of Pathophysiology and Allergy Research, Medical University of Vienna, Waehringer Guertel, Vienna, Austria; NRC Institute of Immunology FMBA of Russia, Moscow, Russia; Laboratory for Immunopathology, Department of Clinical Immunology and Allergy, Sechenov First Moscow State Medical University, Moscow, Russia.
| |
Collapse
|
15
|
Valenta R, Karaulov A, Niederberger V, Zhernov Y, Elisyutina O, Campana R, Focke-Tejkl M, Curin M, Namazova-Baranova L, Wang JY, Pawankar R, Khaitov M. Allergen Extracts for In Vivo Diagnosis and Treatment of Allergy: Is There a Future? J Allergy Clin Immunol Pract 2018; 6:1845-1855.e2. [PMID: 30297269 PMCID: PMC6390933 DOI: 10.1016/j.jaip.2018.08.032] [Citation(s) in RCA: 48] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/02/2018] [Revised: 08/27/2018] [Accepted: 08/31/2018] [Indexed: 02/07/2023]
Abstract
Today, in vivo allergy diagnosis and allergen-specific immunotherapy (AIT) are still based on allergen extracts obtained from natural allergen sources. Several studies analyzing the composition of natural allergen extracts have shown severe problems regarding their quality such as the presence of undefined nonallergenic materials, contaminants as well as high variabilities regarding contents and biological activity of individual allergens. Despite the increasing availability of sophisticated analytical technologies, these problems cannot be overcome because they are inherent to allergen sources and methods of extract production. For in vitro allergy diagnosis problems related to natural allergen extracts have been largely overcome by the implementation of recombinant allergen molecules that are defined regarding purity and biological activity. However, no such advances have been made for allergen preparations to be used in vivo for diagnosis and therapy. No clinical studies have been performed for allergen extracts available for in vivo allergy diagnosis that document safety, sensitivity, and specificity of the products. Only for very few therapeutic allergen extracts state-of-the-art clinical studies have been performed that provide evidence for safety and efficacy. In this article, we discuss problems related to the inconsistent quality of products based on natural allergen extracts and share our observations that most of the products available for in vivo diagnosis and AIT do not meet the international standards for medicinal products. We argue that a replacement of natural allergen extracts by defined recombinantly produced allergen molecules and/or mixtures thereof may be the only way to guarantee the supply of clinicians with state-of-the-art medicinal products for in vivo diagnosis and treatment of allergic patients in the future.
Collapse
Affiliation(s)
- Rudolf Valenta
- Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria; NRC Institute of Immunology FMBA of Russia, Moscow, Russia; Laboratory for Immunopathology, Department of Clinical Immunology and Allergy, Sechenov First Moscow State Medical University, Moscow, Russia.
| | - Alexander Karaulov
- Laboratory for Immunopathology, Department of Clinical Immunology and Allergy, Sechenov First Moscow State Medical University, Moscow, Russia
| | - Verena Niederberger
- Department of Otorhinolaryngology, Medical University of Vienna, Vienna, Austria
| | - Yury Zhernov
- NRC Institute of Immunology FMBA of Russia, Moscow, Russia
| | | | - Raffaela Campana
- Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Margarete Focke-Tejkl
- Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Mirela Curin
- Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Leyla Namazova-Baranova
- Department of Pediatrics, Pirogov Russian National Research Medical University, Moscow, Russia
| | - Jiu-Yao Wang
- Center for Allergy and Immunology Research (ACIR), College of Medicine, National Cheng Kung University (Hospital), Tainan, Taiwan
| | - Ruby Pawankar
- Division of Allergy, Department of Pediatrics, Nippon Medical School, Tokyo, Japan
| | - Musa Khaitov
- NRC Institute of Immunology FMBA of Russia, Moscow, Russia
| |
Collapse
|
16
|
Gadermaier E, Marth K, Lupinek C, Campana R, Hofer G, Blatt K, Smiljkovic D, Roder U, Focke-Tejkl M, Vrtala S, Keller W, Valent P, Valenta R, Flicker S. Isolation of a high-affinity Bet v 1-specific IgG-derived ScFv from a subject vaccinated with hypoallergenic Bet v 1 fragments. Allergy 2018; 73:1425-1435. [PMID: 29315611 PMCID: PMC6032869 DOI: 10.1111/all.13394] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/22/2017] [Indexed: 12/11/2022]
Abstract
Background Recombinant hypoallergenic allergen derivatives have been used in clinical immunotherapy studies, and clinical efficacy seems to be related to the induction of blocking IgG antibodies recognizing the wild‐type allergens. However, so far no treatment‐induced IgG antibodies have been characterized. Objective To clone, express, and characterize IgG antibodies induced by vaccination with two hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1 in a nonallergic subject. Methods A phage‐displayed combinatorial single‐chain fragment (ScFv) library was constructed from blood of the immunized subject and screened for Bet v 1‐reactive antibody fragments. ScFvs were tested for specificity and cross‐reactivity to native Bet v 1 and related pollen and food allergens, and epitope mapping was performed. Germline ancestor genes of the antibody were analyzed with the ImMunoGeneTics (IMGT) database. The affinity to Bet v 1 and cross‐reactive allergens was determined by surface plasmon resonance measurements. The ability to inhibit patients’ IgE binding to ELISA plate‐bound allergens and allergen‐induced basophil activation was assessed. Results A combinatorial ScFv library was obtained from the vaccinated donor after three injections with the Bet v 1 fragments. Despite being almost in germline configuration, ScFv (clone H3‐1) reacted with high affinity to native Bet v 1 and homologous allergens, inhibited allergic patients’ polyclonal IgE binding to Bet v 1, and partially suppressed allergen‐induced basophil activation. Conclusion Immunization with unfolded hypoallergenic allergen derivatives induces high‐affinity antibodies even in nonallergic subjects which recognize the folded wild‐type allergens and inhibit polyclonal IgE binding of allergic patients.
Collapse
Affiliation(s)
- E. Gadermaier
- Division of Immunopathology; Institute of Pathophysiology and Allergy Research; Center for Pathophysiology, Infectiology and Immunology; Vienna General Hospital; Medical University of Vienna; Vienna Austria
| | - K. Marth
- Division of Immunopathology; Institute of Pathophysiology and Allergy Research; Center for Pathophysiology, Infectiology and Immunology; Vienna General Hospital; Medical University of Vienna; Vienna Austria
| | - C. Lupinek
- Division of Immunopathology; Institute of Pathophysiology and Allergy Research; Center for Pathophysiology, Infectiology and Immunology; Vienna General Hospital; Medical University of Vienna; Vienna Austria
| | - R. Campana
- Division of Immunopathology; Institute of Pathophysiology and Allergy Research; Center for Pathophysiology, Infectiology and Immunology; Vienna General Hospital; Medical University of Vienna; Vienna Austria
| | - G. Hofer
- Institute of Molecular Biosciences; BioTechMed, University of Graz; Graz Austria
| | - K. Blatt
- Division of Hematology and Hemostaseology; Department of Internal Medicine I; Vienna General Hospital; Medical University of Vienna; Vienna Austria
| | - D. Smiljkovic
- Division of Hematology and Hemostaseology; Department of Internal Medicine I; Vienna General Hospital; Medical University of Vienna; Vienna Austria
| | - U. Roder
- GE Healthcare Europe GmbH; Freiburg Germany
| | - M. Focke-Tejkl
- Division of Immunopathology; Institute of Pathophysiology and Allergy Research; Center for Pathophysiology, Infectiology and Immunology; Vienna General Hospital; Medical University of Vienna; Vienna Austria
| | - S. Vrtala
- Division of Immunopathology; Institute of Pathophysiology and Allergy Research; Center for Pathophysiology, Infectiology and Immunology; Vienna General Hospital; Medical University of Vienna; Vienna Austria
| | - W. Keller
- Institute of Molecular Biosciences; BioTechMed, University of Graz; Graz Austria
| | - P. Valent
- Division of Hematology and Hemostaseology; Department of Internal Medicine I; Vienna General Hospital; Medical University of Vienna; Vienna Austria
| | - R. Valenta
- Division of Immunopathology; Institute of Pathophysiology and Allergy Research; Center for Pathophysiology, Infectiology and Immunology; Vienna General Hospital; Medical University of Vienna; Vienna Austria
- NRC Institute of Immunology FMBA of Russia; Moscow Russia
| | - S. Flicker
- Division of Immunopathology; Institute of Pathophysiology and Allergy Research; Center for Pathophysiology, Infectiology and Immunology; Vienna General Hospital; Medical University of Vienna; Vienna Austria
| |
Collapse
|
17
|
Abstract
PURPOSE OF REVIEW The aim of this article is to discuss how allergen-specific immunotherapy (AIT) can be improved through molecular approaches. We provide a summary of next-generation molecular AIT approaches and of their clinical evaluation. Furthermore, we discuss the potential of next generation molecular AIT forms for the treatment of severe manifestations of allergy and mention possible future molecular strategies for the secondary and primary prevention of allergy. RECENT FINDINGS AIT has important advantages over symptomatic forms of allergy treatment but its further development is limited by the quality of the therapeutic antigen preparations which are derived from natural allergen sources. The field of allergy diagnosis is currently undergoing a dramatic improvement through the use of molecular testing with defined, mainly recombinant allergens which allows high-resolution diagnosis. Several studies demonstrate that molecular testing in early childhood can predict the development of symptomatic allergy later on in life. Clinical studies indicate that molecular AIT approaches have the potential to improve therapy of allergic diseases and may be used as allergen-specific forms of secondary and eventually primary prevention for allergy.
Collapse
Affiliation(s)
- Mirela Curin
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria
| | - Musa Khaitov
- NRC Institute of Immunology FMBA of Russia, Moscow, Russia
| | - Alexander Karaulov
- Laboratory of Immunopathology, Department of Clinical Immunology and Allergy, Sechenov First Moscow State Medical University, Moscow, Russia
| | | | - Raffaela Campana
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria
| | - Victoria Garib
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria
- International Network of Universities for Molecular Allergololgy and Immunology, Vienna, Austria
| | - Rudolf Valenta
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
- NRC Institute of Immunology FMBA of Russia, Moscow, Russia.
- International Network of Universities for Molecular Allergololgy and Immunology, Vienna, Austria.
| |
Collapse
|
18
|
Eckl-Dorna J, Fröschl R, Lupinek C, Kiss R, Gattinger P, Marth K, Campana R, Mittermann I, Blatt K, Valent P, Selb R, Mayer A, Gangl K, Steiner I, Gamper J, Perkmann T, Zieglmayer P, Gevaert P, Valenta R, Niederberger V. Intranasal administration of allergen increases specific IgE whereas intranasal omalizumab does not increase serum IgE levels-A pilot study. Allergy 2018; 73:1003-1012. [PMID: 29083477 PMCID: PMC5969304 DOI: 10.1111/all.13343] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/24/2017] [Indexed: 02/06/2023]
Abstract
Background Administration of the therapeutic anti‐IgE antibody omalizumab to patients induces strong increases in IgE antibody levels. Objective To investigate the effect of intranasal administration of major birch pollen allergen Bet v 1, omalizumab or placebo on the levels of total and allergen‐specific IgE in patients with birch pollen allergy. Methods Based on the fact that intranasal allergen application induces rises of systemic allergen‐specific IgE, we performed a double‐blind placebo‐controlled pilot trial in which birch pollen allergic subjects were challenged intranasally with omalizumab, placebo or birch pollen allergen Bet v 1. Total and allergen‐specific IgE, IgG and basophil sensitivity were measured before and 8 weeks after challenge. For control purposes, total, allergen‐specific IgE levels and omalizumab‐IgE complexes as well as specific IgG levels were studied in subjects treated subcutaneously with either omalizumab or placebo. Effects of omalizumab on IgE production by IL‐4/anti‐CD40‐treated PBMCs from allergic patients were studied in vitro. Results Intranasal challenge with Bet v 1 induced increases in Bet v 1‐specific IgE levels by a median of 59.2%, and this change differed significantly from the other treatment groups (P = .016). No relevant change in allergen‐specific and total IgE levels was observed in subjects challenged with omalizumab. Addition of omalizumab did not enhance IL‐4/anti‐CD40‐induced IgE production in vitro. Significant rises in total IgE (mean IgE before: 131.83 kU/L to mean IgE after: 505.23 kU/L) and the presence of IgE‐omalizumab complexes were observed after subcutaneous administration of omalizumab. Conclusion Intranasal administration of allergen induced rises of allergen‐specific IgE levels, whereas intranasal administration of omalizumab did not enhance systemic total or allergen‐specific IgE levels.
Collapse
Affiliation(s)
- J. Eckl-Dorna
- Department of Otorhinolaryngology; Medical University of Vienna; Vienna Austria
| | - R. Fröschl
- Clinical Institute for Laboratory Medicine; Medical University of Vienna; Vienna Austria
| | - C. Lupinek
- Division of Immunopathology; Department of Pathophysiology and Allergy Research; Center for Pathophysiology, Infectiology and Immunology; Medical University of Vienna; Vienna Austria
| | - R. Kiss
- Division of Immunopathology; Department of Pathophysiology and Allergy Research; Center for Pathophysiology, Infectiology and Immunology; Medical University of Vienna; Vienna Austria
| | - P. Gattinger
- Division of Immunopathology; Department of Pathophysiology and Allergy Research; Center for Pathophysiology, Infectiology and Immunology; Medical University of Vienna; Vienna Austria
| | - K. Marth
- Division of Immunopathology; Department of Pathophysiology and Allergy Research; Center for Pathophysiology, Infectiology and Immunology; Medical University of Vienna; Vienna Austria
| | - R. Campana
- Division of Immunopathology; Department of Pathophysiology and Allergy Research; Center for Pathophysiology, Infectiology and Immunology; Medical University of Vienna; Vienna Austria
| | - I. Mittermann
- Division of Immunopathology; Department of Pathophysiology and Allergy Research; Center for Pathophysiology, Infectiology and Immunology; Medical University of Vienna; Vienna Austria
| | - K. Blatt
- Division of Hematology and Hemostaseology; Department of Internal Medicine I; Medical University of Vienna; Vienna Austria
| | - P. Valent
- Division of Hematology and Hemostaseology; Department of Internal Medicine I; Medical University of Vienna; Vienna Austria
| | - R. Selb
- Department of Otorhinolaryngology; Medical University of Vienna; Vienna Austria
| | - A. Mayer
- Department of Otorhinolaryngology; Medical University of Vienna; Vienna Austria
| | - K. Gangl
- Department of Otorhinolaryngology; Medical University of Vienna; Vienna Austria
| | - I. Steiner
- Center for Medical Statistics, Informatics, and Intelligent Systems; Section for Medical Statistics; Medical University of Vienna; Vienna Austria
| | - J. Gamper
- Center for Medical Statistics, Informatics, and Intelligent Systems; Section for Medical Statistics; Medical University of Vienna; Vienna Austria
| | - T. Perkmann
- Clinical Institute for Laboratory Medicine; Medical University of Vienna; Vienna Austria
| | | | - P. Gevaert
- Upper Airway Research Laboratory (URL); Ghent University Hospital; Ghent Belgium
| | - R. Valenta
- Division of Immunopathology; Department of Pathophysiology and Allergy Research; Center for Pathophysiology, Infectiology and Immunology; Medical University of Vienna; Vienna Austria
| | - V. Niederberger
- Department of Otorhinolaryngology; Medical University of Vienna; Vienna Austria
| |
Collapse
|
19
|
Valenta R, Karaulov A, Niederberger V, Gattinger P, van Hage M, Flicker S, Linhart B, Campana R, Focke-Tejkl M, Curin M, Eckl-Dorna J, Lupinek C, Resch-Marat Y, Vrtala S, Mittermann I, Garib V, Khaitov M, Valent P, Pickl WF. Molecular Aspects of Allergens and Allergy. Adv Immunol 2018; 138:195-256. [PMID: 29731005 DOI: 10.1016/bs.ai.2018.03.002] [Citation(s) in RCA: 68] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Immunoglobulin E (IgE)-associated allergy is the most common immune disorder. More than 30% of the population suffer from symptoms of allergy which are often severe, disabling, and life threatening such as asthma and anaphylaxis. Population-based birth cohort studies show that up to 60% of the world population exhibit IgE sensitization to allergens, of which most are protein antigens. Thirty years ago the first allergen-encoding cDNAs have been isolated. In the meantime, the structures of most of the allergens relevant for disease in humans have been solved. Here we provide an update regarding what has been learned through the use of defined allergen molecules (i.e., molecular allergology) and about mechanisms of allergic disease in humans. We focus on new insights gained regarding the process of sensitization to allergens, allergen-specific secondary immune responses, and mechanisms underlying allergic inflammation and discuss open questions. We then show how molecular forms of diagnosis and specific immunotherapy are currently revolutionizing diagnosis and treatment of allergic patients and how allergen-specific approaches may be used for the preventive eradication of allergy.
Collapse
Affiliation(s)
- Rudolf Valenta
- Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria; NRC Institute of Immunology FMBA of Russia, Moscow, Russia.
| | - Alexander Karaulov
- Laboratory of Immunopathology, Department of Clinical Immunology and Allergy, Sechenov First Moscow State Medical University, Moscow, Russia
| | - Verena Niederberger
- Department of Otorhinolaryngology, Medical University of Vienna, Vienna, Austria
| | - Pia Gattinger
- Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Marianne van Hage
- Department of Medicine Solna, Immunology and Allergy Unit, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
| | - Sabine Flicker
- Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Birgit Linhart
- Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Raffaela Campana
- Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Margarete Focke-Tejkl
- Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Mirela Curin
- Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Julia Eckl-Dorna
- Department of Otorhinolaryngology, Medical University of Vienna, Vienna, Austria
| | - Christian Lupinek
- Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Yvonne Resch-Marat
- Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Susanne Vrtala
- Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Irene Mittermann
- Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Victoria Garib
- Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria; International Network of Universities for Molecular Allergology and Immunology, Vienna, Austria
| | - Musa Khaitov
- NRC Institute of Immunology FMBA of Russia, Moscow, Russia
| | - Peter Valent
- Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria
| | - Winfried F Pickl
- Institute of Immunology, Medical University of Vienna, Vienna, Austria
| |
Collapse
|
20
|
Perinelli DR, Lucarini S, Fagioli L, Campana R, Vllasaliu D, Duranti A, Casettari L. Lactose oleate as new biocompatible surfactant for pharmaceutical applications. Eur J Pharm Biopharm 2017; 124:55-62. [PMID: 29258912 DOI: 10.1016/j.ejpb.2017.12.008] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2017] [Revised: 11/20/2017] [Accepted: 12/15/2017] [Indexed: 10/18/2022]
Abstract
Sugar fatty acid esters are an interesting class of non-ionic, biocompatible and biodegradable sugar-based surfactants, recently emerged as a valid alternative to the traditional commonly employed (e.g. polysorbates and polyethylene glycol derivatives). By varying the polar head (carbohydrate moiety) and the hydrophobic tail (fatty acid), surfactants with different physico-chemical characteristics can be easily prepared. While many research papers have focused on sucrose derivatives, relatively few studies have been carried out on lactose-based surfactants. In this work, we present the synthesis and the physico-chemical characterization of lactose oleate. The new derivative was obtained by enzymatic mono-esterification of lactose with oleic acid. Thermal, surface, and aggregation properties of the surfactant were studied in detail and the cytotoxicity profile was investigated by MTS and LDH assays on intestinal Caco-2 monolayers. Transepithelial electrical resistance (TEER) measurements on Caco-2 cells showed a transient and reversible effect on the tight junctions opening, which correlates with the increased permeability of 4 kDa fluorescein-labelled dextran (as model for macromolecular drugs) in a concentration dependent manner. Moreover, lactose oleate displayed a satisfactory antimicrobial activity over a range of Gram-positive and Gram-negative bacteria. Overall, the obtained results are promising for a further development of lactose oleate as an intestinal absorption enhancer and/or an alternative biodegradable preservative for pharmaceutical and food applications.
Collapse
Affiliation(s)
- D R Perinelli
- School of Pharmacy, University of Camerino, Via Gentile III da Varano, Camerino (MC) 62032, Italy
| | - S Lucarini
- Department of Biomolecular Sciences, University of Urbino Carlo Bo, Piazza del Rinascimento n° 6, Urbino (PU) 61029, Italy
| | - L Fagioli
- Department of Biomolecular Sciences, University of Urbino Carlo Bo, Piazza del Rinascimento n° 6, Urbino (PU) 61029, Italy
| | - R Campana
- Department of Biomolecular Sciences, University of Urbino Carlo Bo, Piazza del Rinascimento n° 6, Urbino (PU) 61029, Italy
| | - D Vllasaliu
- School of Pharmacy, University of Lincoln, Brayford Pool, Lincoln LN6 7TS, UK
| | - A Duranti
- Department of Biomolecular Sciences, University of Urbino Carlo Bo, Piazza del Rinascimento n° 6, Urbino (PU) 61029, Italy
| | - L Casettari
- Department of Biomolecular Sciences, University of Urbino Carlo Bo, Piazza del Rinascimento n° 6, Urbino (PU) 61029, Italy.
| |
Collapse
|
21
|
Ciacci C, Manti A, Canonico B, Campana R, Camisassi G, Baffone W, Canesi L. Responses of Mytilus galloprovincialis hemocytes to environmental strains of Vibrio parahaemolyticus, Vibrio alginolyticus, Vibrio vulnificus. Fish Shellfish Immunol 2017; 65:80-87. [PMID: 28390964 DOI: 10.1016/j.fsi.2017.04.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/01/2017] [Revised: 03/28/2017] [Accepted: 04/04/2017] [Indexed: 06/07/2023]
Abstract
Marine bivalves are exposed to different types of bacteria in the surrounding waters, in particular of the Vibrio genus. In the hemocytes of the mussel Mytilus spp. immune responses to different vibrios have been largely characterized. However, little information is available on the hemocyte responses to human pathogenic vibrios commonly detected in coastal waters and bivalve tissues that are involved in seafood-borne diseases. In this work, functional parameters of the hemocytes from the Mediterranean mussel M. galloprovincialis were evaluated in response to in vitro challenge with different vibrios isolated from environmental samples of the Adriatic sea (Italy): V. parahaemolyticus Conero, V. alginolyticus 1513 and V. vulnificus 509. V. parahaemolyticus ATCC 43996 was used for comparison. At the 50:1 bacteria hemocyte ratio, only V. parahaemolyticus strains induced significant lysosomal membrane destabilisation. Stimulation of extracellular lysozyme release, total ROS, O2- and NO production were observed, although to different extents and with distinct time courses for different vibrios, V. vulnificus 509 in particular. Further comparisons between V. parahaemolyticus Conero and V. vulnificus 509 showed that only the latter induced dysregulation of the phosphorylation state of p38 MAP Kinase and apoptotic processes. The results indicate that mussel hemocytes can mount an efficient immune response towards V. parahaemolyticus and V. alginolyticus strains, whereas V. vulnificus 509 may affect the hemocyte function. This is the first report on immune responses of mussels to local environmental isolates of human pathogenic vibrios. These data reinforce the hypothesis that Mytilus hemocytes show specific responses to different vibrio species and strains.
Collapse
Affiliation(s)
- C Ciacci
- Department of Biomolecular Science (DISB), University of Urbino "Carlo Bo", Urbino, Italy
| | - A Manti
- Department of Biomolecular Science (DISB), University of Urbino "Carlo Bo", Urbino, Italy
| | - B Canonico
- Department of Biomolecular Science (DISB), University of Urbino "Carlo Bo", Urbino, Italy
| | - R Campana
- Department of Biomolecular Science (DISB), University of Urbino "Carlo Bo", Urbino, Italy
| | - G Camisassi
- Department of Earth, Environment and Life Sciences (DISTAV), University of Genova, Italy
| | - W Baffone
- Department of Biomolecular Science (DISB), University of Urbino "Carlo Bo", Urbino, Italy
| | - L Canesi
- Department of Earth, Environment and Life Sciences (DISTAV), University of Genova, Italy.
| |
Collapse
|
22
|
Ciandrini E, Campana R, Baffone W. Live and heat-killed Lactobacillus spp. interfere with Streptococcus mutans and Streptococcus oralis during biofilm development on titanium surface. Arch Oral Biol 2017; 78:48-57. [DOI: 10.1016/j.archoralbio.2017.02.004] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2016] [Revised: 01/25/2017] [Accepted: 02/03/2017] [Indexed: 12/31/2022]
|
23
|
Valenta R, Campana R, Niederberger V. Recombinant allergy vaccines based on allergen-derived B cell epitopes. Immunol Lett 2017; 189:19-26. [PMID: 28472641 PMCID: PMC6390931 DOI: 10.1016/j.imlet.2017.04.015] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2017] [Accepted: 04/26/2017] [Indexed: 01/01/2023]
Abstract
Immunoglobulin E (IgE)-associated allergy is the most common immunologically-mediated hypersensitivity disease. It affects more than 25% of the population. In IgE-sensitized subjects, allergen encounter can causes a variety of symptoms ranging from hayfever (allergic rhinoconjunctivitis) to asthma, skin inflammation, food allergy and severe life-threatening anaphylactic shock. Allergen-specific immunotherapy (AIT) is based on vaccination with the disease-causing allergens. AIT is an extremely effective, causative and disease-modifying treatment. However, administration of natural allergens can cause severe side effects and the quality of natural allergen extracts limits its application. Research in the field of molecular allergen characterization has allowed deciphering the molecular structures of the disease-causing allergens and it has become possible to engineer novel molecular allergy vaccines which precisely target the mechanisms of the allergic immune response and even appear suitable for prophylactic allergy vaccination. Here we discuss recombinant allergy vaccines which are based on allergen-derived B cell epitopes regarding their molecular and immunological properties and review the results obtained in clinical studies with this new type of allergy vaccines.
Collapse
Affiliation(s)
- Rudolf Valenta
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Medical University Vienna, Vienna, Austria.
| | - Raffaela Campana
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Medical University Vienna, Vienna, Austria
| | - Verena Niederberger
- Department of Otorhinolaryngology, Medical University of Vienna, Vienna, Austria
| |
Collapse
|
24
|
Hochwallner H, Schulmeister U, Swoboda I, Focke-Tejkl M, Reininger R, Civaj V, Campana R, Thalhamer J, Scheiblhofer S, Balic N, Horak F, Ollert M, Papadopoulos NG, Quirce S, Szepfalusi Z, Herz U, van Tol EAF, Spitzauer S, Valenta R. Infant milk formulas differ regarding their allergenic activity and induction of T-cell and cytokine responses. Allergy 2017; 72:416-424. [PMID: 27455132 PMCID: PMC5321598 DOI: 10.1111/all.12992] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/21/2016] [Indexed: 12/15/2022]
Abstract
Background Several hydrolyzed cow's milk (CM) formulas are available for avoidance of allergic reactions in CM‐allergic children and for prevention of allergy development in high‐risk infants. Our aim was to compare CM formulas regarding the presence of immunoreactive CM components, IgE reactivity, allergenic activity, ability to induce T‐cell proliferation, and cytokine secretion. Methods A blinded analysis of eight CM formulas, one nonhydrolyzed, two partially hydrolyzed (PH), four extensively hydrolyzed (EH), and one amino acid formula, using biochemical techniques and specific antibody probes was conducted. IgE reactivity and allergenic activity of the formulas were tested with sera from CM‐allergic patients (n = 26) in RAST‐based assays and with rat basophils transfected with the human FcεRI, respectively. The induction of T‐cell proliferation and the secretion of cytokines in Peripheral blood mononuclear cell (PBMC) culture from CM allergic patients and nonallergic individuals were assessed. Results Immune‐reactive α‐lactalbumin and β‐lactoglobulin were found in the two PH formulas and casein components in one of the EH formulas. One PH formula and the EH formula containing casein components showed remaining IgE reactivity, whereas the other hydrolyzed formulas lacked IgE reactivity. Only two EH formulas and the amino acid formula did not induce T‐cell proliferation and proinflammatory cytokine release. The remaining formulas varied regarding the induction of Th2, Th1, and proinflammatory cytokines. Conclusion Our results show that certain CM formulas without allergenic and low proinflammatory properties can be identified and they may also explain different outcomes obtained in clinical studies using CM formulas.
Collapse
Affiliation(s)
- H. Hochwallner
- Division of Immunopathology; Department of Pathophysiology and Allergy Research; Medical University of Vienna; Vienna Austria
| | - U. Schulmeister
- Department of Medical & Chemical Laboratory Diagnostics; Medical University of Vienna; Vienna Austria
| | - I. Swoboda
- Division of Immunopathology; Department of Pathophysiology and Allergy Research; Medical University of Vienna; Vienna Austria
| | - M. Focke-Tejkl
- Division of Immunopathology; Department of Pathophysiology and Allergy Research; Medical University of Vienna; Vienna Austria
| | - R. Reininger
- Department of Medical & Chemical Laboratory Diagnostics; Medical University of Vienna; Vienna Austria
| | - V. Civaj
- Division of Immunopathology; Department of Pathophysiology and Allergy Research; Medical University of Vienna; Vienna Austria
| | - R. Campana
- Division of Immunopathology; Department of Pathophysiology and Allergy Research; Medical University of Vienna; Vienna Austria
| | - J. Thalhamer
- Department of Molecular Biology; Christian Doppler Laboratory for Allergy Diagnosis & Therapy; University of Salzburg; Salzburg Austria
| | - S. Scheiblhofer
- Department of Molecular Biology; Christian Doppler Laboratory for Allergy Diagnosis & Therapy; University of Salzburg; Salzburg Austria
| | - N. Balic
- Department of Medical & Chemical Laboratory Diagnostics; Medical University of Vienna; Vienna Austria
| | - F. Horak
- Allergy Centre Vienna West; Vienna Austria
| | - M. Ollert
- Department of Infection and Immunity; Luxembourg Institute of Health (LIH); Esch-sur-Alzette, Luxembourg; Germany
- Department of Dermatology and Allergy Center; Odense Research Center for Anaphylaxis; University of Southern Denmark; Odense Denmark
| | - N. G. Papadopoulos
- Allergy Research Center; 2nd Pediatric Clinic; University of Athens; Athens Greece
- Center for Pediatrics and Child Health; Institute of Human Development; University of Manchester; Manchester UK
| | - S. Quirce
- Department of Allergy; Hospital La Paz Institute for Health Research (IdiPAZ); Madrid Spain
| | - Z. Szepfalusi
- Department of Pediatrics; Medical University of Vienna; Vienna Austria
| | - U. Herz
- Mead Johnson Nutrition; Evansville IN USA
| | | | - S. Spitzauer
- Department of Medical & Chemical Laboratory Diagnostics; Medical University of Vienna; Vienna Austria
| | - R. Valenta
- Division of Immunopathology; Department of Pathophysiology and Allergy Research; Medical University of Vienna; Vienna Austria
| |
Collapse
|
25
|
Cabauatan CR, Campana R, Niespodziana K, Reinisch C, Lundberg U, Meinke A, Henning R, Neubauer A, Valenta R. Heat-labile Escherichia coli toxin enhances the induction of allergen-specific IgG antibodies in epicutaneous patch vaccination. Allergy 2017; 72:164-168. [PMID: 27568860 PMCID: PMC5215485 DOI: 10.1111/all.13036] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/26/2016] [Indexed: 11/27/2022]
Abstract
Epicutaneous allergen-specific immunotherapy (EPIT) is proposed as an alternative route for allergen-specific immunotherapy (AIT). The induction of allergen-specific blocking IgG antibodies represents an important mechanism underlying AIT, but has not been investigated for EPIT. Here, we compared the induction of allergen-specific blocking IgG in outbred guinea pigs which had been immunized with recombinant birch pollen allergen Bet v 1 using patch delivery system (PDS) with or without heat-labile toxin (LT) from Escherichia coli or subcutaneously with aluminum hydroxide (Alum)-adsorbed rBet v 1. Only subcutaneous immunization with Alum-adsorbed rBet v 1 and epicutaneous administration of rBet v 1 with PDS in combination with LT from E. coli induced allergen-specific IgG antibodies blocking allergic patients' IgE, but not immunization with rBet v 1 via PDS alone. Our results suggest that patch vaccination with rBet v 1 in combination with LT may be a promising strategy for allergen-specific immunotherapy against birch pollen allergy.
Collapse
Affiliation(s)
- C. R. Cabauatan
- Division of Immunopathology; Department of Pathophysiology and Allergy Research; Center for Pathophysiology, Infectiology and Immunology; Medical University of Vienna; Vienna Austria
| | - R. Campana
- Division of Immunopathology; Department of Pathophysiology and Allergy Research; Center for Pathophysiology, Infectiology and Immunology; Medical University of Vienna; Vienna Austria
| | - K. Niespodziana
- Division of Immunopathology; Department of Pathophysiology and Allergy Research; Center for Pathophysiology, Infectiology and Immunology; Medical University of Vienna; Vienna Austria
| | - C. Reinisch
- Valneva Austria GmbH; Campus Vienna Biocenter; Vienna Austria
| | - U. Lundberg
- Valneva Austria GmbH; Campus Vienna Biocenter; Vienna Austria
| | - A. Meinke
- Valneva Austria GmbH; Campus Vienna Biocenter; Vienna Austria
| | | | | | - R. Valenta
- Division of Immunopathology; Department of Pathophysiology and Allergy Research; Center for Pathophysiology, Infectiology and Immunology; Medical University of Vienna; Vienna Austria
| |
Collapse
|
26
|
Valenta R, Campana R, Focke-Tejkl M, Niederberger V. Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel mechanisms of action for the future. J Allergy Clin Immunol 2016; 137:351-7. [PMID: 26853127 PMCID: PMC4861208 DOI: 10.1016/j.jaci.2015.12.1299] [Citation(s) in RCA: 126] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2015] [Revised: 12/18/2015] [Accepted: 12/18/2015] [Indexed: 11/26/2022]
Abstract
In the past, the development of more effective, safe, convenient, broadly applicable, and easy to manufacture vaccines for allergen-specific immunotherapy (AIT) has been limited by the poor quality of natural allergen extracts. Progress made in the field of molecular allergen characterization has now made it possible to produce defined vaccines for AIT and eventually for preventive allergy vaccination based on recombinant DNA technology and synthetic peptide chemistry. Here we review the characteristics of recombinant and synthetic allergy vaccines that have reached clinical evaluation and discuss how molecular vaccine approaches can make AIT more safe and effective and thus more convenient. Furthermore, we discuss how new technologies can facilitate the reproducible manufacturing of vaccines of pharmaceutical grade for inhalant, food, and venom allergens. Allergy vaccines in clinical trials based on recombinant allergens, recombinant allergen derivatives, and synthetic peptides allow us to target selectively different immune mechanisms, and certain of those show features that might make them applicable not only for therapeutic but also for prophylactic vaccination.
Collapse
Affiliation(s)
- Rudolf Valenta
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Vienna, Austria.
| | - Raffaela Campana
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Vienna, Austria
| | - Margit Focke-Tejkl
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Vienna, Austria
| | | |
Collapse
|
27
|
Huang HJ, Curin M, Banerjee S, Chen KW, Garmatiuk T, Resch Y, Campana R, Focke-Tejkl M, Valenta R, Vrtala S. Towards a non-allergenic peptide mix containing the T cell epitopes of the clinically most relevant house dust mite allergens for tolerance induction. The Journal of Immunology 2016. [DOI: 10.4049/jimmunol.196.supp.192.5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Abstract
House dust mites are one of the most important allergen sources. Der p 1, Der p 2, Der p 5, Der p 7, Der p 21 and Der p 23 are the clinically most important house dust mite (HDM) allergens. The aim of this study was to define a mix of non-allergenic T cell epitope-containing peptides of these allergens for tolerance induction. According to the amino acid sequences of these allergens, we synthesized and purified 33 overlapping peptides covering the complete sequences of Der p 1, 2, 5, 7, 21 and 23. The peptides were tested for IgE and IgG reactivity with sera from HDM allergic patients in ELISA. PBMCs from 27 HDM allergic and 10 non-HDM allergic individuals were incubated with the synthetic peptides and T cell proliferation was measured using a CFSE dilution-based assay. The peptides could be purified in large amounts. They lacked secondary structure but most of them remained soluble in physiological buffers. ELISA assays indicated that most peptides from Derp 1, 2, 5, 7, 21 and 23 lacked IgE reactivity and thus were non-allergenic. T cell proliferation assays identified 12 predominant epitopes in the Der p allergens. Our data indicates that a reasonable number of non-allergenic peptides including the sequences and thus T cell epitopes of the clinically most relevant house dust mite allergens can be defined for prevention of HDM allergy by tolerance induction.
Collapse
|
28
|
Marisaldi M, Argan A, Ursi A, Gjesteland T, Fuschino F, Labanti C, Galli M, Tavani M, Pittori C, Verrecchia F, D'Amico F, Østgaard N, Mereghetti S, Campana R, Cattaneo P, Bulgarelli A, Colafrancesco S, Dietrich S, Longo F, Gianotti F, Giommi P, Rappoldi A, Trifoglio M, Trois A. Enhanced detection of terrestrial gamma-ray flashes by AGILE. Geophys Res Lett 2015; 42:9481-9487. [PMID: 27773951 PMCID: PMC5054821 DOI: 10.1002/2015gl066100] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/07/2015] [Revised: 10/16/2015] [Accepted: 10/19/2015] [Indexed: 06/06/2023]
Abstract
At the end of March 2015 the onboard software configuration of the Astrorivelatore Gamma a Immagini Leggero (AGILE) satellite was modified in order to disable the veto signal of the anticoincidence shield for the minicalorimeter instrument. The motivation for such a change was the understanding that the dead time induced by the anticoincidence prevented the detection of a large fraction of Terrestrial Gamma-Ray Flashes (TGFs). The configuration change was highly successful resulting in an increase of one order of magnitude in TGF detection rate. As expected, the largest fraction of the new events has short duration (<100 μs), and part of them has simultaneous association with lightning sferics detected by the World Wide Lightning Location Network. The new configuration provides the largest TGF detection rate surface density (TGFs/km2/yr) to date, opening prospects for improved correlation studies with lightning and atmospheric parameters on short spatial and temporal scales along the equatorial region.
Collapse
Affiliation(s)
- M. Marisaldi
- INAF‐IASFNational Institute for AstrophysicsBolognaItaly
- Birkeland Centre for Space Science, Department of Physics and TechnologyUniversity of BergenNorway
| | | | - A. Ursi
- INAF‐IAPS RomaRomeItaly
- Dipartimento di FisicaUniversità Tor VergataRomeItaly
| | - T. Gjesteland
- Birkeland Centre for Space Science, Department of Physics and TechnologyUniversity of BergenNorway
- Department of Engineering SciencesUniversity of AgderNorway
| | - F. Fuschino
- INAF‐IASFNational Institute for AstrophysicsBolognaItaly
- Dipartimento di Fisica e AstronomiaUniversità di BolognaBolognaItaly
| | - C. Labanti
- INAF‐IASFNational Institute for AstrophysicsBolognaItaly
| | | | - M. Tavani
- INAF‐IAPS RomaRomeItaly
- Dipartimento di FisicaUniversità Tor VergataRomeItaly
| | - C. Pittori
- ASI Science Data CenterRomeItaly
- INAF‐OARMonteporzio CatoneRomeItaly
| | - F. Verrecchia
- ASI Science Data CenterRomeItaly
- INAF‐OARMonteporzio CatoneRomeItaly
| | | | - N. Østgaard
- Birkeland Centre for Space Science, Department of Physics and TechnologyUniversity of BergenNorway
| | | | - R. Campana
- INAF‐IASFNational Institute for AstrophysicsBolognaItaly
| | | | - A. Bulgarelli
- INAF‐IASFNational Institute for AstrophysicsBolognaItaly
| | - S. Colafrancesco
- INAF‐OARMonteporzio CatoneRomeItaly
- School of PhysicsUniversity of the WitwatersrandJohannesburgSouth Africa
| | | | - F. Longo
- Dipartimento di FisicaUniversità di TriesteTriesteItaly
- INFN TriesteTriesteItaly
| | - F. Gianotti
- INAF‐IASFNational Institute for AstrophysicsBolognaItaly
| | | | | | - M. Trifoglio
- INAF‐IASFNational Institute for AstrophysicsBolognaItaly
| | - A. Trois
- INAF‐Osservatorio Astronomico di CagliariCapoterraItaly
| |
Collapse
|
29
|
Campana R, Moritz K, Marth K, Neubauer A, Huber H, Henning R, Blatt K, Hoermann G, Brodie TM, Kaider A, Valent P, Sallusto F, Wöhrl S, Valenta R. Frequent occurrence of T cell-mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments. J Allergy Clin Immunol 2015; 137:601-609.e8. [PMID: 26518092 PMCID: PMC4748398 DOI: 10.1016/j.jaci.2015.08.042] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2015] [Revised: 08/05/2015] [Accepted: 08/18/2015] [Indexed: 11/18/2022]
Abstract
Background Late allergic reactions are common in the course of allergen-specific immunotherapy and even occur with allergy vaccines with reduced IgE reactivity. Objective We sought to study atopy patch test (APT) reactions and T-cell responses to the recombinant birch pollen allergen Bet v 1 and recombinant hypoallergenic T-cell epitope–containing Bet v 1 fragments in patients with birch pollen allergy with and without atopic dermatitis (AD). Methods A clinical study was conducted in 15 patients with birch pollen allergy with AD (group 1), 5 patients with birch pollen allergy without AD (group 2), 5 allergic patients without birch pollen allergy (group 3), and 5 nonallergic subjects (group 4) by performing skin prick tests and APTs with rBet v 1 and hypoallergenic rBet v 1 fragments. T-cell, cutaneous lymphocyte antigen (CLA)+ and CCR4+ T-cell and cytokine responses were studied by thymidine uptake, carboxyfluorescein diacetate succinimidyl ester staining, and Luminex technology, respectively. Results rBet v 1 and hypoallergenic rBet v 1 fragments induced APT reactions in not only most of the patients with birch pollen allergy with AD (11/15) but also in most of those without AD (4/5). Patients with birch pollen allergy with AD had higher Bet v 1–specific proliferation of CLA+ and CCR4+ T cells compared with patients with birch pollen allergy without AD. There were no differences in Bet v 1–specific CLA+ and CCR4+ proliferation and cytokine secretion in patients with and without APT reactions. Conclusion Hypoallergenic rBet v 1 fragments induce T cell–dependent late reactions not only in patients with birch pollen allergy with AD but also in those without AD, which can be determined based on APT results but not based on in vitro parameters.
Collapse
MESH Headings
- Adult
- Allergens/immunology
- Antigens, Plant/immunology
- Betula/adverse effects
- Cytokines/biosynthesis
- Dermatitis, Atopic/diagnosis
- Dermatitis, Atopic/immunology
- Dermatitis, Atopic/metabolism
- Female
- Histamine Release
- Humans
- Hypersensitivity, Delayed/diagnosis
- Hypersensitivity, Delayed/immunology
- Hypersensitivity, Delayed/metabolism
- Hypersensitivity, Immediate/diagnosis
- Hypersensitivity, Immediate/immunology
- Hypersensitivity, Immediate/metabolism
- Lymphocyte Activation/immunology
- Male
- Patch Tests
- Pollen/immunology
- Rhinitis, Allergic, Seasonal/diagnosis
- Rhinitis, Allergic, Seasonal/immunology
- T-Cell Antigen Receptor Specificity/immunology
- T-Lymphocytes/immunology
- T-Lymphocytes/metabolism
- Young Adult
Collapse
Affiliation(s)
- Raffaela Campana
- Division of Immunopathology, Department of Pathophysiology, Center of Physiology and Pathophysiology, Vienna General Hospital (AKH), Medical University of Vienna, Vienna, Austria
| | - Katharina Moritz
- Division of Immunology, Allergy and Infectious Diseases (DIAID), Department of Dermatology, Vienna General Hospital (AKH), Medical University of Vienna, Vienna, Austria
| | - Katharina Marth
- Division of Immunopathology, Department of Pathophysiology, Center of Physiology and Pathophysiology, Vienna General Hospital (AKH), Medical University of Vienna, Vienna, Austria
| | | | - Hans Huber
- Biomay AG, Vienna Competence Center, Vienna, Austria
| | | | - Katharina Blatt
- Division of Hematology and Hemostaseology, Department of Internal Medicine I, Vienna General Hospital (AKH), Medical University of Vienna, Vienna, Austria
| | - Gregor Hoermann
- Department of Laboratory Medicine, Vienna General Hospital (AKH), Medical University of Vienna, Vienna, Austria
| | - Tess M Brodie
- Cellular Immunology Laboratory, Institute for Research in Biomedicine, University of Italian Switzerland, Bellinzona, Switzerland
| | - Alexandra Kaider
- Center for Medical Statistics, Informatics and Intelligent Systems, Section for Clinical Biometrics, Medical University of Vienna, Vienna, Austria
| | - Peter Valent
- Division of Hematology and Hemostaseology, Department of Internal Medicine I, Vienna General Hospital (AKH), Medical University of Vienna, Vienna, Austria
| | - Federica Sallusto
- Cellular Immunology Laboratory, Institute for Research in Biomedicine, University of Italian Switzerland, Bellinzona, Switzerland
| | - Stefan Wöhrl
- Division of Immunology, Allergy and Infectious Diseases (DIAID), Department of Dermatology, Vienna General Hospital (AKH), Medical University of Vienna, Vienna, Austria
| | - Rudolf Valenta
- Division of Immunopathology, Department of Pathophysiology, Center of Physiology and Pathophysiology, Vienna General Hospital (AKH), Medical University of Vienna, Vienna, Austria.
| |
Collapse
|
30
|
Eckl‐Dorna J, Campana R, Valenta R, Niederberger V. Poor association of allergen-specific antibody, T- and B-cell responses revealed with recombinant allergens and a CFSE dilution-based assay. Allergy 2015; 70:1222-9. [PMID: 26043182 PMCID: PMC4949646 DOI: 10.1111/all.12661] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/28/2015] [Indexed: 11/29/2022]
Abstract
BACKGROUND The adaptive immunity underlying allergy comprises two components, the allergen-specific antibody (i.e. IgE, IgG) and the T-cell response. These two components are responsible for different disease manifestations and can be targeted by different therapeutic approaches. Here, we investigated the association of allergen-specific antibody and T- as well as B-cell responses in pollen-allergic patients using recombinant (r) major birch pollen allergen rBet v 1 and major timothy grass pollen allergen rPhl p 5 as defined antigens. METHODS Allergen-specific IgE and IgG antibody responses were determined by ELISA, and allergen-specific T- and B-cell responses were measured in peripheral blood mononuclear cells using a carboxyfluorescein-diacetate-succinimidylester (CFSE) dilution assay. RESULTS CFSE staining in combination with T-cell- and B-cell-specific gating allowed discriminating between allergen-specific T-cell and B-cell responses. Interestingly, we identified patients where mainly T cells and others where mainly B cells proliferated in response to allergen stimulation. No association between the level of allergen-specific Ig responses and B- or T-cell proliferation was observed. CONCLUSION Purified recombinant allergens in conjunction with CFSE staining allow the dissection of allergen-specific B- and T-cell responses. The dissociation of allergen-specific antibody, and B- and T-cell responses may explain the occurrence of selective IgE- and T-cell-mediated manifestations of allergic inflammation and may be important for the development of diagnostic and therapeutic strategies selectively targeting B cells and T cells.
Collapse
Affiliation(s)
- J. Eckl‐Dorna
- Department of Otorhinolaryngology Medical University of Vienna Vienna Austria
| | - R. Campana
- Division of Immunopathology Department of Pathophysiology and Allergy Research Center for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria
| | - R. Valenta
- Division of Immunopathology Department of Pathophysiology and Allergy Research Center for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria
| | - V. Niederberger
- Department of Otorhinolaryngology Medical University of Vienna Vienna Austria
| |
Collapse
|
31
|
Hochwallner H, Schulmeister U, Herz U, Focke-Tejkl M, Swoboda I, Reininger R, Civaj V, Campana R, Thalhamer J, Scheiblhofer S. Allergenic activity and ability to induce T cell and cytokine responses of different infant milk formulas. World Allergy Organ J 2015. [PMCID: PMC4407071 DOI: 10.1186/1939-4551-8-s1-a253] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
32
|
Canonico B, Campana R, Luchetti F, Arcangeletti M, Betti M, Cesarini E, Ciacci C, Vittoria E, Galli L, Papa S, Baffone W. Campylobacter jejuni cell lysates differently target mitochondria and lysosomes on HeLa cells. Apoptosis 2014; 19:1225-42. [DOI: 10.1007/s10495-014-1005-0] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
33
|
Rosati P, Triunfo S, Zucchetti F, Gorca C, Chini R, Campana R. [Screening of obesity, overweight and thinness in a children population in Rome, Italy]. Minerva Pediatr 2014; 66:201-207. [PMID: 24826976] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
AIM Objective of the study was to estimate the prevalence of obesity, overweight and thinness in a children population in Rome, Italy. METHODS The study sample was created, after informed consent, in a school in Rome, available to the study project. A total of 595 children (289 males, 306 females), aged between 6 to 19 years, underwent following measurements: height and weight, evaluation of body mass index. RESULTS A normal BMI was recorded in 73.6% of cases. Morbid obesity, obesity, overweight, and thinness grade 1 and 2 prevalence was 1.2%, 4%, 15.3%, 9.2% and 3.8%, respectively, without statistical differences in both genders, except the prevalence of overweight that resulted statistically significant (11.4% females vs. 19.3% males, P<0.05). Differences in the age groups have been found. About 17.2% and 18.7% of children between 7 to 11 years were overweight and obese and about 33.3% and 26.6% between 6 to 8 years thin grade 1 and 2, respectively. CONCLUSION The study suggests a prevalence of overweight and obesity in our sample lower than that reported in a recent epidemiological survey carried out on Italy. Attention must be taken to underweight, particularly with regard to the most severe form, as a public health problem for all possible risks correlated. In addition, our study shows the involvement of specific age groups. This finding, if confirmed in a larger population, should be associated with a major attention on specific age groups at risk, in order to plan an appropriate treatment program.
Collapse
Affiliation(s)
- P Rosati
- Dipartimento di Ostetricia e Ginecologia Università Cattolica del Sacro Cuore Roma, Italia -
| | | | | | | | | | | |
Collapse
|
34
|
Cabauatan C, Campana R, Niespodziana K, Reinisch C, Lundberg U, Meinke A, Henning R, Neubauer A, Valenta R. Induction of allergen-specific blocking IgG using patch delivered recombinant Bet v 1 in guinea pigs. Clin Transl Allergy 2014. [PMCID: PMC4072013 DOI: 10.1186/2045-7022-4-s2-o18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
35
|
Focke-Tejkl M, Campana R, Reininger R, Lupinek C, Blatt K, Valent P, Pavkov-Keller T, Keller W, Valenta R. Dissection of the IgE and T-cell recognition of the major group 5 grass pollen allergen Phl p 5. J Allergy Clin Immunol 2014; 133:836-45.e11. [PMID: 24182774 PMCID: PMC6624141 DOI: 10.1016/j.jaci.2013.08.038] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2012] [Revised: 08/08/2013] [Accepted: 08/26/2013] [Indexed: 01/01/2023]
Abstract
BACKGROUND The major timothy grass pollen allergen Phl p 5 belongs to the most potent allergens involved in hay fever and asthma. OBJECTIVE This study characterized immune-dominant IgE- and T-cell-recognition sites of Phl p 5. METHODS Seven peptides, P1 to P7 with a length of 31 to 38 amino acids that spanned the Phl p 5 sequence, were synthesized, characterized by circular dichroism spectroscopy, and tested for IgE reactivity, basophil activation, and T-cell reactivity. Carrier-bound peptides were studied for their ability to induce IgG antibodies in rabbits which recognize Phl p 5 or cross-reactive allergens from different grass species. Peptide-specific antibodies were tested for the capability to inhibit IgE reactivity to Phl p 5 and allergen-induced basophil activation of patients with allergy. RESULTS The peptides exhibited no secondary structure and showed no IgE reactivity or relevant allergenic activity, indicating that Phl p 5 IgE epitopes are conformational. Except for P3, peptide-specific IgG antibodies blocked IgE binding to Phl p 5 of patients with allergy and cross-reacted with temperate grasses. IgE inhibition experiments and molecular modeling identified several clustered conformational IgE epitopes on the N- as well as C-terminal domain of Phl p 5. P4, which stimulated the strongest T-cell and cytokine responses in patients, was not part of the major IgE-reactive regions. CONCLUSION Our study shows an interesting dissociation of the major IgE- and T-cell-reactive domains in Phl p 5 which provides a basis for the development of novel forms of immunotherapy that selectively target IgE or T-cell responses.
Collapse
Affiliation(s)
- Margarete Focke-Tejkl
- Christian Doppler Laboratory for Allergy Research, Medical University of Vienna, Vienna, Austria; Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Raffaela Campana
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Renate Reininger
- Christian Doppler Laboratory for Allergy Research, Medical University of Vienna, Vienna, Austria
| | - Christian Lupinek
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Katharina Blatt
- Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
| | - Peter Valent
- Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
| | - Tea Pavkov-Keller
- Institute of Molecular Biosciences, University of Graz, Graz, Austria
| | - Walter Keller
- Institute of Molecular Biosciences, University of Graz, Graz, Austria
| | - Rudolf Valenta
- Christian Doppler Laboratory for Allergy Research, Medical University of Vienna, Vienna, Austria; Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
| |
Collapse
|
36
|
Donnarumma I, Tramacere A, Turriziani S, Costamante L, Campana R, De Rosa A, Bozzo E. A new insight into the innermost jet regions: probing extreme jet variability with LOFT. EPJ Web of Conferences 2013. [DOI: 10.1051/epjconf/20136104015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
37
|
Abstract
Immunoglobulin E-mediated allergies affect more than 25% of the population. Allergen exposure induces a variety of symptoms in allergic patients, which include rhinitis, conjunctivitis, asthma, dermatitis, food allergy and life-threatening systemic anaphylaxis. At present, allergen-specific immunotherapy (SIT), which is based on the administration of the disease-causing allergens, is the only disease-modifying treatment for allergy. Current therapeutic allergy vaccines are still prepared from relatively poorly defined allergen extracts. However, with the availability of the structures of the most common allergen molecules, it has become possible to produce well-defined recombinant and synthetic allergy vaccines that allow specific targeting of the mechanisms of allergic disease. Here we provide a summary of the development and mechanisms of SIT, and then review new forms of therapeutic vaccines that are based on recombinant and synthetic molecules. Finally, we discuss possible allergen-specific strategies for prevention of allergic disease.
Collapse
Affiliation(s)
- R Valenta
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Austria.
| | | | | | | |
Collapse
|
38
|
Szymanski C, Campana R, Magne J, Rosca M, Pierard L, Lancellotti P. Quantitative assessment of left ventricular function by 2D-speckle tracking during exercise: A feasibility study. Arch Cardiovasc Dis 2011. [DOI: 10.1016/j.acvd.2011.03.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
39
|
Tavani M, Bulgarelli A, Vittorini V, Pellizzoni A, Striani E, Caraveo P, Weisskopf MC, Tennant A, Pucella G, Trois A, Costa E, Evangelista Y, Pittori C, Verrecchia F, Del Monte E, Campana R, Pilia M, De Luca A, Donnarumma I, Horns D, Ferrigno C, Heinke CO, Trifoglio M, Gianotti F, Vercellone S, Argan A, Barbiellini G, Cattaneo PW, Chen AW, Contessi T, D’Ammando F, DeParis G, Di Cocco G, Di Persio G, Feroci M, Ferrari A, Galli M, Giuliani A, Giusti M, Labanti C, Lapshov I, Lazzarotto F, Lipari P, Longo F, Fuschino F, Marisaldi M, Mereghetti S, Morelli E, Moretti E, Morselli A, Pacciani L, Perotti F, Piano G, Picozza P, Prest M, Rapisarda M, Rappoldi A, Rubini A, Sabatini S, Soffitta P, Vallazza E, Zambra A, Zanello D, Lucarelli F, Santolamazza P, Giommi P, Salotti L, Bignami GF. Discovery of Powerful Gamma-Ray Flares from the Crab Nebula. Science 2011; 331:736-9. [DOI: 10.1126/science.1200083] [Citation(s) in RCA: 249] [Impact Index Per Article: 19.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Affiliation(s)
- M. Tavani
- Istituto Nazionale di Astrofisica–Istituto di Astrofisica Spaziale e Fisica Cosmica (INAF-IASF) Roma, via del Fosso del Cavaliere 100, 00133 Roma, Italy
- Dipartimento di Fisica, Università degli Studi di Roma “Tor Vergata,” via della Ricerca Scientifica 1, 00133 Roma, Italy
- Consorzio Interuniversitario Fisica Spaziale (CIFS), villa Gualino, v.le Settimio Severo 63, 10133 Torino, Italy
- Istituto Nazionale di Fisica Nucleare (INFN) Roma Tor Vergata, via della Ricerca Scientifica 1, 00133 Roma, Italy
| | - A. Bulgarelli
- INAF-IASF Bologna, via Gobetti 101, 40129 Bologna, Italy
| | - V. Vittorini
- Istituto Nazionale di Astrofisica–Istituto di Astrofisica Spaziale e Fisica Cosmica (INAF-IASF) Roma, via del Fosso del Cavaliere 100, 00133 Roma, Italy
| | - A. Pellizzoni
- INAF Osservatorio Astronomico di Cagliari, Poggio dei Pini, 09012 Capoterra, Italy
| | - E. Striani
- Dipartimento di Fisica, Università degli Studi di Roma “Tor Vergata,” via della Ricerca Scientifica 1, 00133 Roma, Italy
- Istituto Nazionale di Fisica Nucleare (INFN) Roma Tor Vergata, via della Ricerca Scientifica 1, 00133 Roma, Italy
| | - P. Caraveo
- INAF-IASF Milano, via E. Bassini 15, 20133 Milano, Italy
| | - M. C. Weisskopf
- NASA, Marshall Space Flight Center, Huntsville, AL 35812, USA
| | - A. Tennant
- NASA, Marshall Space Flight Center, Huntsville, AL 35812, USA
| | - G. Pucella
- Ente per le Nuove tecnologie, l’Energia e l’Ambiente (ENEA) Frascati, via Enrico Fermi 45, 00044 Frascati(RM), Italy
| | - A. Trois
- Istituto Nazionale di Astrofisica–Istituto di Astrofisica Spaziale e Fisica Cosmica (INAF-IASF) Roma, via del Fosso del Cavaliere 100, 00133 Roma, Italy
| | - E. Costa
- Istituto Nazionale di Astrofisica–Istituto di Astrofisica Spaziale e Fisica Cosmica (INAF-IASF) Roma, via del Fosso del Cavaliere 100, 00133 Roma, Italy
| | - Y. Evangelista
- Istituto Nazionale di Astrofisica–Istituto di Astrofisica Spaziale e Fisica Cosmica (INAF-IASF) Roma, via del Fosso del Cavaliere 100, 00133 Roma, Italy
| | - C. Pittori
- Agenzia Spatiale Italiana (ASI) Science Data Center, European Space Agency (ESA) Centre for Earth Observation (ESRIN), 00044 Frascati, Italy
| | - F. Verrecchia
- Agenzia Spatiale Italiana (ASI) Science Data Center, European Space Agency (ESA) Centre for Earth Observation (ESRIN), 00044 Frascati, Italy
| | - E. Del Monte
- Istituto Nazionale di Astrofisica–Istituto di Astrofisica Spaziale e Fisica Cosmica (INAF-IASF) Roma, via del Fosso del Cavaliere 100, 00133 Roma, Italy
| | - R. Campana
- Istituto Nazionale di Astrofisica–Istituto di Astrofisica Spaziale e Fisica Cosmica (INAF-IASF) Roma, via del Fosso del Cavaliere 100, 00133 Roma, Italy
| | - M. Pilia
- INAF Osservatorio Astronomico di Cagliari, Poggio dei Pini, 09012 Capoterra, Italy
- Dipartimento di Fisica, Università degli Studi dell’ Insubria, via Valleggio 11, 22100, Como, Italy
| | - A. De Luca
- INAF-IASF Milano, via E. Bassini 15, 20133 Milano, Italy
- Istituto Universitario di Studi Superiori (IUSS), I-27100 Pavia, Italy
| | - I. Donnarumma
- Istituto Nazionale di Astrofisica–Istituto di Astrofisica Spaziale e Fisica Cosmica (INAF-IASF) Roma, via del Fosso del Cavaliere 100, 00133 Roma, Italy
| | - D. Horns
- Institut fuer Experimentalphysik, University of Hamburg, Hamburg 22761, Germany
| | - C. Ferrigno
- Integral Science Data Centre, University of Geneva, Geneva Chemin d’Ecogia 16, CH-1290 Versoix, Switzerland
| | - C. O. Heinke
- Department of Physics, University of Alberta, Edmonton, Alberta T6G 2G7, Canada
| | - M. Trifoglio
- INAF-IASF Bologna, via Gobetti 101, 40129 Bologna, Italy
| | - F. Gianotti
- INAF-IASF Bologna, via Gobetti 101, 40129 Bologna, Italy
| | - S. Vercellone
- INAF-IASF Palermo, via La Malfa 153, 90146 Palermo, Italy
| | - A. Argan
- Istituto Nazionale di Astrofisica–Istituto di Astrofisica Spaziale e Fisica Cosmica (INAF-IASF) Roma, via del Fosso del Cavaliere 100, 00133 Roma, Italy
| | - G. Barbiellini
- Consorzio Interuniversitario Fisica Spaziale (CIFS), villa Gualino, v.le Settimio Severo 63, 10133 Torino, Italy
- Dipartimento di Fisica, Università di Trieste, via A. Valerio 2, 34127 Trieste, Italy
- INFN Trieste, Padriciano 99, 34012 Trieste, Italy
| | | | - A. W. Chen
- Consorzio Interuniversitario Fisica Spaziale (CIFS), villa Gualino, v.le Settimio Severo 63, 10133 Torino, Italy
- INAF-IASF Milano, via E. Bassini 15, 20133 Milano, Italy
| | - T. Contessi
- INAF-IASF Milano, via E. Bassini 15, 20133 Milano, Italy
| | - F. D’Ammando
- INAF-IASF Palermo, via La Malfa 153, 90146 Palermo, Italy
| | - G. DeParis
- Istituto Nazionale di Astrofisica–Istituto di Astrofisica Spaziale e Fisica Cosmica (INAF-IASF) Roma, via del Fosso del Cavaliere 100, 00133 Roma, Italy
| | - G. Di Cocco
- INAF-IASF Bologna, via Gobetti 101, 40129 Bologna, Italy
| | - G. Di Persio
- Istituto Nazionale di Astrofisica–Istituto di Astrofisica Spaziale e Fisica Cosmica (INAF-IASF) Roma, via del Fosso del Cavaliere 100, 00133 Roma, Italy
| | - M. Feroci
- Istituto Nazionale di Astrofisica–Istituto di Astrofisica Spaziale e Fisica Cosmica (INAF-IASF) Roma, via del Fosso del Cavaliere 100, 00133 Roma, Italy
| | - A. Ferrari
- Consorzio Interuniversitario Fisica Spaziale (CIFS), villa Gualino, v.le Settimio Severo 63, 10133 Torino, Italy
- Dipartimento di Fisica Generale, Università degli Studi di Torino, via P. Giuria 1, 10125 Torino, Italy
| | - M. Galli
- ENEA Bologna, via don Fiammelli 2, 40128 Bologna, Italy
| | - A. Giuliani
- INAF-IASF Milano, via E. Bassini 15, 20133 Milano, Italy
| | - M. Giusti
- Istituto Nazionale di Astrofisica–Istituto di Astrofisica Spaziale e Fisica Cosmica (INAF-IASF) Roma, via del Fosso del Cavaliere 100, 00133 Roma, Italy
- Consorzio Interuniversitario Fisica Spaziale (CIFS), villa Gualino, v.le Settimio Severo 63, 10133 Torino, Italy
| | - C. Labanti
- INAF-IASF Bologna, via Gobetti 101, 40129 Bologna, Italy
| | - I. Lapshov
- Space Research Institute, Russian Academy of Sciences, 84/32 Profsoyuznaya Street, 117997 Moscow, Russia
| | - F. Lazzarotto
- Istituto Nazionale di Astrofisica–Istituto di Astrofisica Spaziale e Fisica Cosmica (INAF-IASF) Roma, via del Fosso del Cavaliere 100, 00133 Roma, Italy
| | - P. Lipari
- INFN Roma 1, p.le Aldo Moro 2, 00185 Roma, Italy
- Dipartimento di Fisica, Università degli Studi di Roma “La Sapienza,” p.le Aldo Moro 2, 00185 Roma, Italy
| | - F. Longo
- Dipartimento di Fisica, Università di Trieste, via A. Valerio 2, 34127 Trieste, Italy
- INFN Trieste, Padriciano 99, 34012 Trieste, Italy
| | - F. Fuschino
- INAF-IASF Bologna, via Gobetti 101, 40129 Bologna, Italy
| | - M. Marisaldi
- INAF-IASF Bologna, via Gobetti 101, 40129 Bologna, Italy
| | - S. Mereghetti
- INAF-IASF Milano, via E. Bassini 15, 20133 Milano, Italy
| | - E. Morelli
- INAF-IASF Bologna, via Gobetti 101, 40129 Bologna, Italy
| | - E. Moretti
- Dipartimento di Fisica, Università di Trieste, via A. Valerio 2, 34127 Trieste, Italy
- INFN Trieste, Padriciano 99, 34012 Trieste, Italy
| | - A. Morselli
- Istituto Nazionale di Fisica Nucleare (INFN) Roma Tor Vergata, via della Ricerca Scientifica 1, 00133 Roma, Italy
| | - L. Pacciani
- Istituto Nazionale di Astrofisica–Istituto di Astrofisica Spaziale e Fisica Cosmica (INAF-IASF) Roma, via del Fosso del Cavaliere 100, 00133 Roma, Italy
| | - F. Perotti
- INAF-IASF Milano, via E. Bassini 15, 20133 Milano, Italy
| | - G. Piano
- Istituto Nazionale di Astrofisica–Istituto di Astrofisica Spaziale e Fisica Cosmica (INAF-IASF) Roma, via del Fosso del Cavaliere 100, 00133 Roma, Italy
- Istituto Nazionale di Fisica Nucleare (INFN) Roma Tor Vergata, via della Ricerca Scientifica 1, 00133 Roma, Italy
| | - P. Picozza
- Istituto Nazionale di Astrofisica–Istituto di Astrofisica Spaziale e Fisica Cosmica (INAF-IASF) Roma, via del Fosso del Cavaliere 100, 00133 Roma, Italy
- Istituto Nazionale di Fisica Nucleare (INFN) Roma Tor Vergata, via della Ricerca Scientifica 1, 00133 Roma, Italy
| | - M. Prest
- Dipartimento di Fisica, Università degli Studi dell’ Insubria, via Valleggio 11, 22100, Como, Italy
| | - M. Rapisarda
- Ente per le Nuove tecnologie, l’Energia e l’Ambiente (ENEA) Frascati, via Enrico Fermi 45, 00044 Frascati(RM), Italy
| | | | - A. Rubini
- Istituto Nazionale di Astrofisica–Istituto di Astrofisica Spaziale e Fisica Cosmica (INAF-IASF) Roma, via del Fosso del Cavaliere 100, 00133 Roma, Italy
| | - S. Sabatini
- Istituto Nazionale di Astrofisica–Istituto di Astrofisica Spaziale e Fisica Cosmica (INAF-IASF) Roma, via del Fosso del Cavaliere 100, 00133 Roma, Italy
- Istituto Nazionale di Fisica Nucleare (INFN) Roma Tor Vergata, via della Ricerca Scientifica 1, 00133 Roma, Italy
| | - P. Soffitta
- Istituto Nazionale di Astrofisica–Istituto di Astrofisica Spaziale e Fisica Cosmica (INAF-IASF) Roma, via del Fosso del Cavaliere 100, 00133 Roma, Italy
| | - E. Vallazza
- INFN Trieste, Padriciano 99, 34012 Trieste, Italy
| | - A. Zambra
- Consorzio Interuniversitario Fisica Spaziale (CIFS), villa Gualino, v.le Settimio Severo 63, 10133 Torino, Italy
- INAF-IASF Milano, via E. Bassini 15, 20133 Milano, Italy
| | - D. Zanello
- INFN Roma 1, p.le Aldo Moro 2, 00185 Roma, Italy
- Dipartimento di Fisica, Università degli Studi di Roma “La Sapienza,” p.le Aldo Moro 2, 00185 Roma, Italy
| | - F. Lucarelli
- Agenzia Spatiale Italiana (ASI) Science Data Center, European Space Agency (ESA) Centre for Earth Observation (ESRIN), 00044 Frascati, Italy
| | - P. Santolamazza
- Agenzia Spatiale Italiana (ASI) Science Data Center, European Space Agency (ESA) Centre for Earth Observation (ESRIN), 00044 Frascati, Italy
| | - P. Giommi
- Agenzia Spatiale Italiana (ASI) Science Data Center, European Space Agency (ESA) Centre for Earth Observation (ESRIN), 00044 Frascati, Italy
| | | | - G. F. Bignami
- Istituto Universitario di Studi Superiori (IUSS), I-27100 Pavia, Italy
| |
Collapse
|
40
|
Vrtala S, Fohr M, Campana R, Baumgartner C, Valent P, Valenta R. Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination. Vaccine 2011; 29:2140-8. [PMID: 21215346 DOI: 10.1016/j.vaccine.2010.12.080] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2010] [Revised: 12/13/2010] [Accepted: 12/20/2010] [Indexed: 10/18/2022]
Abstract
An immunotherapy trial performed in allergic patients with hypoallergenic recombinant fragments, comprising aa 1-74 and 75-160 of the major birch pollen allergen, Bet v 1, has indicated that the induction of allergen-specific IgG responses may be an important mechanism of this treatment. To investigate whether the immunogenicity of the rBet v 1 fragments can be increased, recombinant trimers of the fragments were produced. For this purpose, DNA trimers of rBet v 1 aa 1-74 as well as of rBet v 1 aa 75-160 were subcloned into expression plasmid pET 17b, expressed in Escherichia coli and purified. The fragments as well as the fragment trimers showed a reduced IgE-binding capacity and allergenic activity compared to rBet v 1 wildtype when tested in allergic patients. Both rBet v 1 aa 75-160 monomer and trimer induced high titers of allergen-specific IgG1 Abs in mice. Interestingly, rBet v 1 aa 1-74 trimer induced a much higher IgG(1) response to rBet v 1 than rBet v 1 aa 1-74 monomer. Consequently, IgG Abs induced with the rBet v 1 aa 1-74 trimer inhibited birch pollen allergic patients' IgE-binding 10-fold more efficiently than IgG Abs induced with the monomer. Our data show that the immunogenicity of allergy vaccines can be increased by oligomerization.
Collapse
Affiliation(s)
- Susanne Vrtala
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria
| | | | | | | | | | | |
Collapse
|
41
|
Campana R, Vrtala S, Maderegger B, Dall'Antonia Y, Zafred D, Blatt K, Herrmann H, Focke-Tejkl M, Swoboda I, Scheiblhofer S, Gieras A, Neubauer A, Keller W, Valent P, Thalhamer J, Spitzauer S, Valenta R. Altered IgE epitope presentation: A model for hypoallergenic activity revealed for Bet v 1 trimer. Mol Immunol 2010; 48:431-41. [PMID: 21093057 DOI: 10.1016/j.molimm.2010.09.016] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2009] [Revised: 09/21/2010] [Accepted: 09/27/2010] [Indexed: 11/28/2022]
Abstract
In order to reduce side effects in the course of allergen specific immunotherapy hypoallergenic allergen derivatives with reduced IgE reactivity have been made by genetic engineering. In contrast to other recombinant hypoallergenic allergen derivatives which showed reduced IgE reactivity, a recombinant trimer of the major birch pollen allergen Bet v 1 showed reduced allergenic activity despite preserved IgE reactivity. We studied rBet v 1 trimer by SDS-PAGE, mass spectrometry, circular dichroism and gel filtration. Furthermore we investigated IgE and IgG reactivity of the rBet v 1 trimer in solid and liquid phase assays and compared its allergenic activity with that of rBet v 1 wildtype using basophil activation assays. In solid phase immunoassays rBet v 1 trimer exhibited even stronger IgE reactivity than the rBet v 1 wildtype, whereas both proteins were equally well recognized by Bet v 1-specific IgG antibody probes. In fluid phase IgE experiments rBet v 1 trimer inhibited IgE reactivity to rBet v 1 wildtype but showed a more than 10-fold reduced allergenic activity compared to the rBet v 1 monomer. By analytical gel filtration it was demonstrated that, despite its monomeric appearance in SDS-PAGE the trimer occurred in fluid phase in the form of defined high molecular weight (>600 kDa) aggregates whereas rBet v 1 wildtype strictly appeared as monomeric protein. The results indicate that the hypoallergenic nature of the rBet v 1 trimer is due to formation of defined high molecular weight aggregates which may be responsible for an altered presentation of IgE epitopes in a form with reduced capacity to crosslink effector-cell bound IgE. We thus provide evidence for a novel mechanism for hypoallergenic activity.
Collapse
Affiliation(s)
- Raffaela Campana
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Vienna General Hospital (AKH), Medical University of Vienna, 1090 Vienna, Austria
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Campana R, Vrtala S, Maderegger B, Jertschin P, Stegfellner G, Swoboda I, Focke-Tejkl M, Blatt K, Gieras A, Zafred D, Neubauer A, Valent P, Keller W, Spitzauer S, Valenta R. Hypoallergenic derivatives of the major birch pollen allergen Bet v 1 obtained by rational sequence reassembly. J Allergy Clin Immunol 2010; 126:1024-31, 1031.e1-8. [PMID: 20638112 DOI: 10.1016/j.jaci.2010.05.023] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2009] [Revised: 05/10/2010] [Accepted: 05/18/2010] [Indexed: 12/23/2022]
Abstract
BACKGROUND At least 100 million patients suffer from birch pollen allergy. OBJECTIVE Rational design of recombinant derivatives of the major birch pollen allergen, Bet v 1, characterized by reduced IgE reactivity, preservation of sequences relevant for the induction of allergen-specific blocking IgG, and maintenance of T-cell epitopes for immunotherapy of birch pollen allergy. METHODS Three recombinant mosaic proteins derived from Bet v 1 were generated by reassembly of codon-optimized genes coding for Bet v 1 fragments containing the elements for the induction of allergen-specific blocking IgG antibodies and the major T-cell epitopes. The proteins were expressed in Escherichia coli as recombinant mosaic molecules and compared with the Bet v 1 wild-type protein by chemical and structural methods, regarding IgE-binding and IgG-binding capacity, in basophil activation assays and tested for the in vivo induction of IgG responses. RESULTS Three recombinant Bet v 1 (rBet v 1) mosaic proteins with strongly reduced IgE reactivity and allergenic activity were expressed and purified. Immunization with the recombinant hypoallergens induced IgG antibodies that inhibited IgE reactivity of patients with allergy to Bet v 1 comparable to those induced with the rBet v 1 wild-type allergen. CONCLUSION We report the generation and preclinical characterization of 3 hypoallergenic rBet v 1 derivatives with suitable properties for immunotherapy of birch pollen allergy.
Collapse
Affiliation(s)
- Raffaela Campana
- Division of Immunopathology, Department of Pathophysiology, Center of Pathophysiology, Infectiology and Immunology, Vienna General Hospital (AKH), Medical University of Vienna, Vienna, Austria
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Edlmayr J, Niespodziana K, Linhart B, Focke-Tejkl M, Westritschnig K, Scheiblhofer S, Stoecklinger A, Kneidinger M, Valent P, Campana R, Thalhamer J, Popow-Kraupp T, Valenta R. A Combination Vaccine for Allergy and Rhinovirus Infections Based on Rhinovirus-Derived Surface Protein VP1 and a Nonallergenic Peptide of the Major Timothy Grass Pollen Allergen Phl p 1. J Immunol 2009; 182:6298-306. [DOI: 10.4049/jimmunol.0713622] [Citation(s) in RCA: 70] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
44
|
Gangl K, Reininger R, Bernhard D, Campana R, Pree I, Reisinger J, Kneidinger M, Kundi M, Dolznig H, Thurnher D, Valent P, Chen KW, Vrtala S, Spitzauer S, Valenta R, Niederberger V. Cigarette smoke facilitates allergen penetration across respiratory epithelium. Allergy 2009; 64:398-405. [PMID: 19120070 DOI: 10.1111/j.1398-9995.2008.01861.x] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND The association between cigarette smoke exposure and allergic airway disease is a matter for debate. We sought to investigate in an in vitro system whether active smoking reduces the integrity and barrier function of the respiratory epithelium and thus facilitates allergen penetration. METHODS We cultured the human bronchial epithelial cell line 16HBE14o- in a transwell culture system as a surrogate for the intact respiratory epithelium. The cell monolayer was exposed to standardized cigarette smoke extract (CSE). The extent and effects of trans-epithelial allergen penetration were measured using 125I-labelled purified major respiratory allergens (rBet v 1, rPhl p 5 and rDer p 2) and histamine release experiments. RESULTS Exposure of cells to concentrations of CSE similar to those found in smokers induced the development of para-cellular gaps and a decrease in trans-epithelial resistance. CSE exposure induced a more than threefold increase in allergen penetration. Increased subepithelial allergen concentrations provoked a substantial augmentation of histamine release from sensitized basophils. CONCLUSIONS Our results indicate that cigarette smoke is a potent factor capable of reducing the barrier function of the respiratory epithelium for allergens and may contribute to increased allergic inflammation, exacerbation of allergic disease and boosting of IgE memory.
Collapse
Affiliation(s)
- K Gangl
- Department of Otorhinolaryngology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Campana R, Mothes N, Rauter I, Vrtala S, Reininger R, Focke-Tejkl M, Lupinek C, Balic N, Spitzauer S, Valenta R. Non–IgE-mediated chronic allergic skin inflammation revealed with rBet v 1 fragments. J Allergy Clin Immunol 2008; 121:528-530.e1. [DOI: 10.1016/j.jaci.2007.09.014] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2007] [Revised: 09/06/2007] [Accepted: 09/13/2007] [Indexed: 11/15/2022]
|
46
|
Campana R, Scesa C, Patrone V, Vittoria E, Baffone W. Microbiological study of cosmetic products during their use by consumers: health risk and efficacy of preservative systems. Lett Appl Microbiol 2006; 43:301-6. [PMID: 16910936 DOI: 10.1111/j.1472-765x.2006.01952.x] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
AIM To evaluate the microbial contamination of 91 cosmetics (23 o/w emulsions, 47 tensiolytes, 21 aqueous pastes) in three different states of use (intact, in-use, ending product) and the protection efficacy of the preservative systems most frequently used in the analysed cosmetic formulations. METHODS AND RESULTS Total bacterial count, isolation and identification of pathogenic isolates were performed on the collected cosmetics. About 10.6% of tensiolytes (13.5% bath foam, 6.7% shampoo, 10% liquid soaps) were contaminated by Staphylococcus warneri, Staphylococcus epidermidis and Pseudomonas putida. The efficacy of the preservative systems of two cosmetic products, tested against standard micro-organisms (Staphylococcus aureus ATCC 4338 and Pseudomonas aeruginosa ATCC 9027) and two isolates from cosmetics in this study (S. epidermidis and P. putida), satisfied the Cosmetics, Toiletries, and Fragrance Association and Official Italian Pharmacopeia criteria, while only one tested cosmetic respected the Rapid Challenge Test criterion. CONCLUSIONS Contaminated cosmetic products are relatively uncommon, but some products, unable to suppress the growth of several micro-organisms, represent a potential health hazard. SIGNIFICANCE AND IMPACT OF THE STUDY The challenge test may be performed not only during the preparation of the preservative system in the intact cosmetics, but also be used to evaluate the protection efficacy during their use.
Collapse
Affiliation(s)
- R Campana
- Istituto di Scienze Tossicologiche, Igienistiche ed Ambientali, Università di Urbino Carlo Bo, Urbino, Italy
| | | | | | | | | |
Collapse
|
47
|
Falcioni T, Papa S, Campana R, Mannello F, Casaroli A, Burattini S, Baffone W. Flow cytometric evaluation ofVibrio parahaemolyticus adhesion inhibition to human epithelial cells. Cytometry 2005; 66:25-35. [PMID: 15924304 DOI: 10.1002/cyto.b.20056] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
BACKGROUND The present report demonstrates the usefulness of flow cytometry for a quantitative assessment of adhesion inhibition of a Vibrio parahaemolyticus strain to human epithelial cells to acquire more information about the nature of its adhesins. METHODS The inhibition of the adhesive process to Hep-2 was assayed by adding several monosaccharides to infected cells monolayers. The quantification of the adherent bacteria, labeled with a specific primary antibody plus a secondary fluorescein isothiocyanate-conjugated antibody, was performed by flow cytometry in comparison with light microscopy. The adherence was quantified in terms of the proportion of cells with adherent V. parahaemolyticus and as the mean of adherent bacteria per cell. RESULTS The adhesion showed a percentage of 98% with a mean fluorescence channel of 331 comparable to those obtained by light microscopy. The addition of monosaccharides resulted in a D-mannose and N-acetyl-galactosamine sensitive adherence. Even if this environmental strain also showed a mannose-sensitive cell-associated hemoagglutination that could mediate V. parahaemolyticus adherence, our results suggest that different sites for an irreversible adherence to host cell are involved. CONCLUSIONS Flow cytometry in combination with indirect immunofluorescence is an effective tool to investigate the adhesive process of bacteria to epithelial cells because it is more sensitive and reproducible than visual counting of bacteria performed in light microscopy.
Collapse
Affiliation(s)
- T Falcioni
- Centro di Citometria e Citomorfologia, Università Carlo Bo, Urbino, Italy
| | | | | | | | | | | | | |
Collapse
|
48
|
Baffone W, Vittoria E, Campana R, Citterio B, Casaroli A, Pierfelici L. Occurrence and expression of virulence-related properties by environmental halophilic Vibrio spp. in in vitro and in vivo systems. Food Control 2005. [DOI: 10.1016/j.foodcont.2004.05.006] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
49
|
Baffone W, Casaroli A, Campana R, Citterio B, Vittoria E, Pierfelici L, Donelli G. ‘In vivo’ studies on the pathophysiological mechanism of Vibrio parahaemolyticus TDH+—induced secretion. Microb Pathog 2005; 38:133-7. [PMID: 15748815 DOI: 10.1016/j.micpath.2004.11.001] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2004] [Revised: 11/12/2004] [Accepted: 11/22/2004] [Indexed: 11/16/2022]
Abstract
The thermostable direct haemolysin (TDH) is considered to be the major virulence factors of Vibrio parahaemolyticus; however, poor information is available about its mechanism of action. In our study we examined the capacity of two V. parahaemolyticus TDH-producers (strains 2067 and 3305) to induce fluid secretion in rat ileal loop and to reveal the role of calcium ions (Ca(2+)), calmodulin (CaM), and protein kinase C (PKC) in V. parahaemolyticus TDH(+)-induced fluid secretion. The results show that V. parahaemolyticus TDH(+) strains were able to induce secretion in small intestine; on the contrary, this ability was not evidenced in the V. parahaemolyticus TDH(-) strain used as negative control. The data suggest an enterotoxic activity of haemolysin. Calcium ionophore A23187 and 1-verapamil (calcium channel blocker), when injected alone, induced fluid accumulation in the control loops. A further increase in fluid accumulation (P<0.001) was noted when calcium ionophore was injected along with bacterial suspension of both TDH(+) strains and a significant decrease (P<0.001) in experimental loops when 1-verapamil was inoculated along with bacterial suspension. The other modulating agents increased fluid accumulation in both control and experimental loops, without significant differences with respect to the positive control. Our findings suggest that Ca(2+) appears to be an important messenger involved in the stimulation of intestinal secretion, contrary to PKC and calmodulin which do not appear to have any role.
Collapse
Affiliation(s)
- W Baffone
- Istituto di Scienze Tossicologiche, Igienistiche ed Ambientali, University of Urbino, via S. Chiara 27, 61029 Urbino, Italy.
| | | | | | | | | | | | | |
Collapse
|
50
|
Baffone W, Citterio B, Vittoria E, Casaroli A, Campana R, Falzano L, Donelli G. Retention of virulence in viable but non-culturable halophilic Vibrio spp. Int J Food Microbiol 2003; 89:31-9. [PMID: 14580971 DOI: 10.1016/s0168-1605(03)00102-8] [Citation(s) in RCA: 98] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
The viable but non-culturable (VBNC) forms of two environmental strains of Vibrio alginolyticus 1 and Vibrio parahaemolyticus 66 and one strain of V. parahaemolyticus ATCC 43996 showing virulence characteristics (hemolysin production, adhesive and/or cytotoxic ability, in vivo enteropathogenicity) were obtained by culturing bacteria in a microcosm consisting of artificial sea water (ASW) and incubating at 5 degrees C with shaking. Every 2 days, culturability of the cells in the microcosm was monitored by spread plates on BHI agar and total count and the percentage of viable cells were determined by double staining with DAPI and CTC. When cell growth was not detectable (<0.1 CFU/ml), the population was considered non-culturable and, then, the VBNC forms were resuscitated in a murine model. For each strain, eight male Balb/C mice were intragastrically inoculated with 0.1 ml of concentrated ASW bacterial culture. Two mice from each group were sacrificed at 2, 4, 8, and 12 days after challenge for autopsy and re-isolation of the microorganisms from the intestinal tissue cultures. Isolation was obtained in 25% of the animals challenged with the VBNC V. alginolyticus strain, in 37.5% of those challenged with the VBNC V. parahaemolyticus strain of environmental origin and in 50% of the animals infected with VBNC V. parahaemolyticus ATCC 43996. The strains thus isolated were again subjected to biological assays to determine the retention of pathogenicity. The virulence characteristics that seemed to disappear after resuscitation in the mouse were subsequently reactivated by means of two consecutive passages of the strains in the rat ileal loop model. The results obtained indicate that VBNC forms of the strains examined can be resuscitated and retain their virulence properties.
Collapse
Affiliation(s)
- W Baffone
- Istituto di Scienze Tossicologiche, Igienistiche ed Ambientali, Università degli Studi di Urbino, Via Santa Chiara, 27, 61029 Urbino (PU), Rome, Italy.
| | | | | | | | | | | | | |
Collapse
|